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ABSTRACT  
Curcumin is a secondary metabolite produced by Curcuma longa. Studies have confirmed its 
biological and therapeutic effects in several diseases being the anticancer activity the most 
documented. Since curcumin is synthetized in low amounts, its heterologous production could 
represent a rapid and easy method to obtain large amounts of this bioactive compound. 
Curcumin has already been produced by Escherichia coli. However, the curcumin biosynthetic 
pathway has never been engineered in Saccharomyces cerevisiae. As a eukaryotic organism, 
it presents unique advantages over E. coli regarding the expression of plant derived genes. 
This work aimed to design, construct and validate a biosynthetic pathway composed by genes 
from different plants to produce curcumin from ferulic acid in an engineered S. cerevisiae. The 
enzymes involved in the artificial pathway are: 4-coumarate-CoA ligase (4CL) and different 
type III polyketide synthases (PKSs). In C. longa there are two types of PKSs - diketide-CoA 
synthase (DCS) and curcumin synthase (CURS) - that catalyse different reactions. Curcuminoid 
synthase (CUS) from Oryza sativa is also a PKS and catalysis the “one-pot” synthesis of 
curcuminoids in E. coli. Shuttle vectors with enzymes from different organisms were 
constructed and transformed into two S. cerevisiae strains. The vectors carried 4CL from 
Arabidopsis thaliana or Lithospermum erythrorhizon, and CUS or DCS and CURS. Curcumin was 
visually produced with a pathway composed by 4CL from L. erythrorhizon and CUS from O. 
sativa. The maximal curcumin production was 233.42 ng/L representing a yield of 1.46 %. Also, 
three different extraction methods were tested which revealed the importance of cell lysis in 
curcumin extraction from yeast. In addition, CRISPR-Cas9 method was used to knockout a 
gene from S. cerevisiae that codifies ferulic acid decarboxylase. As expected, the mutant strain 
was not able to consume ferulic acid. However, no curcumin production could be detected in 
the preliminary assays. It is important to mention that this study allowed to produce curcumin 
for the first time in an engineering yeast. In the future, optimizations at genetic and 
operational level are needed to improve the curcumin titters.  
KEYWORDS: CURCUMIN, SACCHAROMYCES CEREVISIAE, CLONING, CRISPR-CAS9 
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RESUMO 
 A curcumina é um metabolito secundário produzido pela Curcuma longa. Vários estudos 
confirmaram o seu efeito biológico e terapêutico em várias doenças sendo a atividade 
anticancerígena a mais documentada. Devido ao facto da curcumina ser sintetizada em 
pequenas quantidades, a sua produção heteróloga pode representar um método rápido e fácil 
para obter grandes quantidades deste composto bioativo. A curcumina já foi produzida em 
Escherichia coli. No entanto, a sua via biossintética nunca foi introduzida em Saccharomyces 
cerevisiae. Como organismo eucariótico, este apresenta vantagens únicas em relação a E. coli 
para expressão de genes derivados de plantas. Este trabalho teve como objetivo projetar, 
construir e validar uma via biossintética composta por genes de diferentes plantas para 
produzir curcumina a partir de ácido ferúlico em S. cerevisiae. As enzimas envolvidas na via 
artificial são: 4-cumárico-CoA ligase (4CL) e as policetídeo sintase tipo III (PKS). Em C. longa 
existem dois tipos de PKSs - diketide-CoA sintase (DCS) e curcumina sintase (CURS) - que 
catalisam reações diferentes. A curcuminoide sintase (CUS) da Oryza sativa é também uma 
PKS. Esta enzima foi capaz a sintetizar curcuminoides em E. coli num só passo. Para esse efeito, 
vetores “shuttle” com enzimas de diferentes organismos foram construídos e transformados 
em duas estirpes de S. cerevisiae. Os vetores possuíam 4CL de Arabidopsis thaliana ou de 
Lithospermum erythrorhizon, e CUS ou DCS e CURS. Foi possível aferir visualmente a produção 
de curcumina nas leveduras onde foi inserida uma via composta por 4CL de L. erythrorhizon e 
CUS de O. sativa. A produção máxima de curcumina foi de 233,42 ng/L, o que representa um 
rendimento mássico de 1,5%.  Além disso, três métodos de extração diferentes foram 
testados, o que demostrou a importância da lise celular para extração de curcumina em 
levedura. Além disso, o método CRISPR-Cas9 foi usado para silenciar um gene em S. cerevisiae 
que codifica a ácido ferúlico descarboxilase. Como esperado, o mutante resultante não foi 
capaz de consumir ácido ferúlico. No entanto, em ensaios preliminares também não foi 
possível detetar a produção de curcumina. É de realçar que este foi o primeiro trabalho em 
que a curcumina foi produzida por uma levedura geneticamente modificada. No futuro, são 
necessárias otimizações a nível genético e operacional por forma a aumentar os rendimentos 
de produção. 
PALAVRAS CHAVE: CURCUMINA, SACCHAROMYCES CEREVISIAE, CLONAGEM, CRISPR-CAS9 
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SCOPE 
 
Cancer has a major impact on society being responsible for 8.8 million of deaths in 
2015 and representing the second leading cause of death worldwide. The number of new 
cases is expected to rise by about 70 % over the next two decades (World Health Organization, 
2017). Great efforts have been made to find therapeutic compounds and ways to produce 
them to reduce cancer mortality. 
Curcumin has been studied extensively due to its anticancer activity. Its effect during 
the various stages of carcinogenesis have been reported, pointing this compound as a 
potential natural drug for cancer treatment. Apart from its anticancer activity, curcumin 
seems to be a very interesting molecule because it presents other biological activities. 
However, curcumin extraction from plants is time-consuming and inefficient since pure 
curcumin is not obtained. Moreover, it is hard to chemically synthesize hampering its 
utilization. The use of microorganisms to produce curcumin presents itself as an innovative 
and economical solution. The yeast Saccharomyces cerevisiae, besides the extensive toolbox 
of genetic modifications and fermentative strategies, possesses the GRAS classification which 
facilitates further applications in the pharmaceutical industries. The current work was 
developed under this scope, aiming the production of curcumin by an engineered yeast.   
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1 STATE-OF-THE-ART  
 Curcumin  
 
The secondary metabolism refers to the metabolic pathways that lead to compounds 
that are not involved in the processes of growth, development and reproduction (Kossel, 
1891). Plants produce a wide variety of secondary metabolites and such compounds are 
characterized by their low abundance and also to be stored in specific organs or cells. They 
are responsible for plant adaptation to the environment acting as protectors against 
pathogens and animals, absorbing UV light, among others (Bourgaud et al., 2001). These 
compounds are classified according to their biosynthetic pathway and are divided in three 
large families: phenolics, terpenes and steroids, and alkaloids (Harborne and Baxter, 1999).  
For centuries, the secondary metabolites have been used in traditional medicine due to their 
biological activity, and nowadays they are also used in pharmaceutics, cosmetics, fine 
chemistry and others (Bourgaud et al., 2001).  
 Turmeric (Curcuma longa) is a perennial herb native from India belonging to ginger 
family and extensively cultivated in southeast tropical Asia. Its rhizome is the most useful part 
and has been used in culinary as spice, in traditional medicine and as coloring agent in foods 
and textiles. Curcuminoids are secondary metabolites produced by C. longa and represent the 
most active compounds of the plant. They have been widely used as yellow food coloring, in 
drugs and cosmetics (Aggarwal et al., 2007). Chemically, they are classified as polyphenols 
more specifically diarylheptanoids. There are three major types of curcuminoids in C. longa: 
curcumin, demethoxycurcumin and bis-demethoxycurcumin (Figure 1). In general, the term 
curcumin is used to designate all the curcuminoids (Anand et al., 2008). Curcumin [IUPAC 
name (1E, 6E)-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-1,6-heptadien-3,5-dione; CAS number: 
458-37-7] is an orange-yellow crystalline powder water insoluble (but soluble in ethanol and 
other organic solvents) and was described in 1910 by Lampe and Milobedeska. The molecular 
formula of curcumin is C21H20O6 and it has a molecular weight of 368.37g/mol. Today there 
are more than 120 known species of Curcuma and pure curcumin is obtained from them by 
solvent extraction and subsequent crystallization. The amount of curcuminoids that can be 
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extracted varies among different species and it depends heavily on the geographical 
conditions (Esatbeyoglu et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.1 Biological activity 
 
Curcumin was first isolated in 1815 by Vogel and Pelletier. Later in 1937 the first study 
of its effect in human disease was published, and in 1949 its antibacterial activity was reported 
by Schraufstätter and Bernt. In the last five decades, several studies confirmed the biological 
effects of curcuminoids in humans and its therapeutic effects were widely described making 
curcumin one of the most studied naturally-derived therapeutic products (Aggarwal et al., 
2007; Epstein et al., 2010; Esatbeyoglu et al., 2012; Joe et al., 2004; Maheshwari et al., 2006; 
Zhang et al., 2013). 
 
 
 
Figure 1: Structures of curcumin, demethoxycurcumin and bis-demethoxycurcumin. 
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1.1.1.1 Anticancer activity 
 
The effect of curcumin has been studied in various human carcinomas, namely liver 
(Chuang et al., 2000), skin (Huang et al., 1995; Jiang et al., 2015), pancreatic(Li et al., 2005), 
prostate (Dorai et al., 2001), ovarian (Cai et al., 2013), lung (Yang et al., 2012), head and neck 
(Azuine and Bhide, 1994; Tanaka et al., 1995) cancers, among others. The anticancer activity 
of this compound is diverse (Table 1), targeting various levels of regulation during the various 
stages of carcinogenesis from DNA mutation to the metastasis and apoptosis (Perrone et al., 
2015; Wilken et al., 2011). 
 
1.1.1.2 Other biological activities 
 
Several studies confirmed other curcumin biological activities besides anticancer. The 
antioxidant activity is one of the most documented effects of curcumin and its derivatives. 
Curcumin showed to act as antioxidant inhibiting lipid peroxidation and other oxidative 
damages. For example,  Unnikrishnan and Rao (1995) concluded that curcumin provided a 
protection to hemoglobin from oxidation induced by nitrogen dioxide. The antioxidant effect 
is related to the presence of phenolic and methoxy groups that contribute to the free-radical-
scavenging (Ruby et al., 1995; Sharma, 1976; Sugiyama et al., 1996). Curcumin showed the 
strongest free-radical-scavenging activity relatively to other curcuminoids due to its 
electrochemical properties (Motterlini et al., 2000). In addition to antioxidant activity, 
curcuminoids present numerous properties that are beneficial to human health (Table 2). 
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Table 1: Some curcumin effect in anticancer activity. 
  Curcumin effect description References 
 
Effect on 
transcription factors 
-Suppresses the expression of gene products involved in 
carcinogenesis and tumor growth (such as COX2); 
(Weir et al. 2007; Park et al., 
2005; Tharakan et al. 2010) 
 
Effect on cell cycle 
regulation 
-Upregulates the expression of the Cip/Kip family of CDK 
inhibitors, thus inhibiting the association of cyclin D1 with 
CDK4 and CDK6; 
-Decreases phosphorylation of Rb and suppresses 
transcription of E2F-regulated genes; 
(Park et al. 2002); 
Mukhopadhyay et al. 2002) 
 
 
Effect on apoptosis 
-Selectively induces apoptosis in G2 phase tumor cells via 
upregulation of p53 expression and initiation of 
mitochondrial apoptotic pathway via increased Bax 
expression and cytochrome c release; 
-Stimulatory effect in extrinsic apoptosis, triggered by the 
binding of “death activators” such as TNF-α and Fas 
Ligand to their cell surface receptors; 
-Promotes the aggregation of Fas receptors and increases 
the levels of caspase-8 and -3; 
(Bush et al., 2001; Wang et al., 
1995; Weir et al., 2007) 
 
Effect in autophagic 
cell death 
-Inhibits the Akt/mTOR/p70S6 kinase pathway and 
ERK1/2 pathway, involved in the regulation of autophagy 
induced by nutrient stress leading to G2/M cell cycle 
arrest and non-apoptotic autophagic death; 
(Jia et al., 2009; O’Sullivan-
Coyne et al.,, 2009) 
 
 
Effect on 
angiogenesis and 
metastasis 
-Regulates a variety of pro-angiogenic growth factors, 
enzymes and transcription factors including bFGF, VEGF, 
angiopoetin-1 and 2, COX-2, MMP-9, AP-1 and NF-κB; 
-Inhibits the angiogenic response to FGF-2 stimulation;  
-Decreases the levels of the angiogenic biomarkers COX-
2 and VEGF;  
-Affects cellular adhesion molecules involved in the 
processes of tumor growth and metastasis 
(Gururaj et al., 2002; Mohan 
et al., 2000; Ray et al., 2003; 
Yoysungnoen et al., 2006) 
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Table 2: Some of the therapeutic effects of curcumin. 
 Curcumin effect description References 
 
Anti- inflammatory 
 
-Inhibits molecules that mediate the inflammatory 
response like COX-2, iNOS through suppression of NF-ĸB; 
(Jobin et al., 1999) 
 
Anti-diabetic 
-Inhibits nuclear factor kappa beta;  
-Inhibits protein carbonyl, lipid peroxidation and 
lysosomal enzyme activities; 
-Decreases the levels of TBARS (Thiobarbituric acid 
reactive substances) and the activity of SDH (Sorbitol 
dehydrogenase); 
-Induces PPAR-y (peroxisome proliferator activated 
receptor gamma); 
-Can elevate plasma insulin level and increase lipoprotein 
lipase activity; 
-Activates enzymes associated with glycolysis, glycogenic 
and lipid metabolism in liver; 
(El-Moselhy et al, 2011; He et al., 
2012; Seo et al., 2008) 
Anti-Alzheimer’s 
- Decreases the accumulation of amyloid β-peptide, and 
markers of oxidative stress and inflammation in the 
cerebral cortex; 
- Stimulates neuroplasticity by acting on Nrf2 and 
promoting the expression of superoxide dismutase, 
catalase, sulfaredoxin, thioredoxin, peroxiredoxin 
systems, glutathione peroxidase, glutathione reductase, 
γ-glutamine cysteine ligase and γ-glutamine cysteine 
synthase, quinone recycling (NAD(P)H quinone 
oxidoreducase, and heme oxygenase 1; 
(Farooqui, 2016; Yang et al., 2005) 
Anti-Parkinson 
- Inhibits aggregation of α-synuclein; 
- Regulates proteins involved in iron metabolism; 
- Inhibits JNK (c-Jun N-terminal kinases) phosphorylation; 
(Mythri and Bharath, 2012;  Wang 
et al., 2010) 
 
 
Anti-HIV 
-Inhibits HIV-1 LTR gene expression; 
-Inhibits p24 antigen production through transcriptional 
repression of LTR; 
-Inhibits HIV-1 and HIV-2 proteases activities; 
-Inhibits HIV-1 integrases activity; 
-Inhibits the acetylation of HIV-Tat protein. 
(Abraham et al., 1993; Mazumder 
et al., 1997) 
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In addition to the properties reported in Table 2 there are many more documented 
biological and medical properties of curcumin in arthritis, pancreatitis, muscle regeneration, 
cystic fibrosis, against cataract formation, in lung and liver injuries, wound healing and scarring 
and in cholesterol lowering and cardiovascular diseases among others (Aggarwal et al., 2007). 
However, contradictory information regarding curcumin biological activities had been 
discussed, mainly in the review article by  Nelson et al. (2017). The authors questioned first 
the use of different types of curcumin in in vivo tests and clinical trials, usually a curcuminoid 
mixture, while in in vitro tests, generally pure synthetic curcumin is used. Secondly, they 
mentioned that curcumin appears to be a PAIN (pan-assay interference compound) exhibiting 
all known PAIN-type behaviour like covalent labelling of proteins, membrane disruption, 
fluorescent interference and structural decomposition causing false-positive results in in vitro 
assays. Despite the reported biological activities in the literature, the authors referred its low 
half life time at physiological conditions, its photoreactivity, solvolysis and oxidative 
degradation responsible for the misleading results because the biological effect may be 
caused by a degradation product. Curcumin also displays undesirable physiochemical 
properties relative to known drugs like forming chemical aggregates and water insolubility. 
Regarding pharmacokinetic and pharmacodynamic properties the authors concluded that 
they are poor due to low absorption, distribution in the body, high potential to be metabolized 
and excreted. Also, curcumin exhibited toxicological effects due its iron chelation activity. The 
authors also referred that curcumin never shown to be conclusively effective in a randomized, 
placebo-controlled clinical trial and concluded that curcumin is “reactive, nonbioavailable and 
therefore a high improbable lead” compound. However, Padmanaban and Nagaraj (2017) 
state that the conclusions taken by Nelson et al. (2017) cannot be drawn and show several 
examples, including clinical trials, where significant beneficial effect of curcumin was 
observed. In conclusion, the authors agree that a cautionary approach is welcome, but that 
curcumin has an enormous potential.  
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1.1.2 Bioavailability 
 
Curcumin is considered as a safe and novel drug for the treatment of a wide range of 
diseases. In numerous phase I studies, adverse effects were not observed in humans taking 
up to 12 g of curcumin per day orally (Vareed et al., 2008). The Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) set an acceptable daily intake value of 0-3 mg/kg body 
weight per day for curcumin in 2004. In 2009, Sabinsa Corporation received a “generally 
regarded as safe” (GRAS) status for the branded ingredient Curcumin C3 Complex® (Majeed 
et al., 2002) after a review of safety and toxicology data by Soni & Associates, Inc. 
Studies on bioavailability of curcuminoids have been performed in numerous 
investigations in rodents and also in humans. Despite curcumin presenting a wide range of 
therapeutic applications, its bioavailability is low due to a relatively low absorption in 
intestine, rapid metabolism in liver and elimination through the gall bladder if administered 
orally. It is only significantly detected in plasma or in tissues after administration of high oral 
doses (Yang et al. 2007). Curcumin is conjugated with glucuronic acid and sulfate in 
enterocytes, these conjugates are actively transported out of the cells through the multidrug 
resistance related proteins (MRP) which accounts for its low bioavailability (Wortelboer et al., 
2003).  
To solve the curcumin low bioavailability, it is necessary to improve its solubility in 
aqueous solutions. The solubility of curcumin can be increased by the formation of complexes 
with metal ions. More recently, other methods showed to improve curcumin bioavailability 
using  piperine, nanoparticles, liposomes or phospholipids (Basnet and Basnet, 2011). Piperine 
works as an adjuvant that blocks the curcuminoids metabolism. However, the use of adjuvants 
may represent a problem because a lot of xenobiotics are detoxified by the same pathway 
(Shoba et al., 1998). Therefore, new approaches are being tested to delivery drugs using 
targeted drug delivery system such as nanoencapsulation. Xie et al. (2011) confirmed that the 
use of PLGA (poly (lactic-co-glycolic acid)) nanoparticles elevates the oral bioavailability of 
curcumin. The same results were obtained using lecithin liposomes and cyclodextrin. In 
addition, the use of analogs of curcumin demonstrated to increase the bioavailability and 
enhanced the therapeutic effects (Yallapu, et al. 2010; Takahashi, et al. 2009). 
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 Curcuminoid biosynthetic pathway in Curcuma longa 
 
Ramirez-Ahumada et al. (2006) reported the first work that identified the enzymes 
involved in the synthesis of curcumin confirming the involvement of the phenylpropanoid 
pathway that channels the carbon flow from primary metabolism to different branch 
pathways of secondary metabolism which includes the synthesis of curcumin. Curcumin, as 
also other curcuminoids, consists of two phenylpropanoid units derived from phenylalanine 
connected by a central carbon derived from malonyl-CoA and this reaction is catalysed by type 
III PKS (Polyketide synthase) enzymes. 
The enzyme phenylalanine ammonia lyase (PAL) is the first enzyme of this pathway 
and it represents a branch point between primary (amino acids metabolism) and secondary 
metabolism (phenylpropanoid pathway). It catalyses the formation of cinnamic acid that is 
converted to p-coumaric acid by cinnamate-4-hydroxylase (C4H). Next, there are two different 
ways for p-coumaric acid metabolism. First, it may be converted in other hydroxycinnamic 
analogues namely ferulic acid by 4-coumarate 3-hydroxylase (C3H) and caffeic acid O-
methyltransferase (COMT) having caffeic acid as intermediate, or it can be activated by 
condensation with malonyl-CoA to form the corresponding CoA ester. This reaction is 
catalysed by 4-coumarate-CoA ligase (4CL). 4CL acts in multiple substrates, activating also the 
other analogues. After activation, p-coumaroyl-CoA can also be converted to the other 
activated analogues, caffeoyl-CoA and feruloyl-CoA by a set of enzymes which include p-
coumaroyl shikimate transferase (CST) and caffeoyl-CoA O-methyltransferase (CCoAOMT). 
The CoA esters are converted to curcuminoids by PKS. However, Ramirez-Ahumada et al., 
(2006) despite detectable curcuminoid synthase activity in in vitro assays, were not able to 
characterize the enzyme(s) responsible for the reaction. The CoA esters are essential 
intermediates not only in the biosynthesis of curcumin but also in the biosynthesis of other 
plant phenolic secondary metabolites exalting the importance of the phenylpropanoid 
pathway in plant secondary metabolism (Ehlting et al., 1999).  
Furthermore, Katsuyama and collaborators (2007) proposed a pathway for the 
curcuminoids synthesis in C. longa including two type III PKS. One, named diketide-CoA 
synthase (DCS), catalyses the formation of feruloyl-diketide-CoA from feruloyl-CoA and 
malonyl-CoA. The other, curcumin synthase 1 (CURS1), catalyses the hydrolysis of feruloyl-
diketide-CoA in a β-keto acid and condensates it with other molecule of feruloyl-CoA forming 
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curcumin. DCS and CURS1 also accept p-coumaroyl-CoA to form bis-desmethoxycurcumin but 
with low efficiency. Later, the same authors (Katsuyama et al. 2009) characterized two other 
type III PKS, CURS2 and CURS3. In vitro analyses confirmed distinct substrates specificities for 
these enzymes. CURS2 uses preferentially feruloyl-CoA while CURS3 uses feruloyl-CoA and 
also p-coumaroyl-CoA. The existence of three different CURS could be the reason to explain 
the distribution of three curcuminoids in C. longa. CURSs and DCS share a conserved Cys-His-
Asn catalytic triad and more than 60% identity (Table 3).  
 
 
Table 3: Identity and kinetic parameters of DCS, CURS1, CURS2 and CURS3 from Curcuma longa. 
 
 
Curcuminoid biosynthetic pathway in C. longa is represented in Figure 2. 
 
 
Enzyme 
 
Identity 
w/ 
DCS 
 
Identity 
w/ CURS1 
 
Identity 
w/ CURS2 
 
Identity 
w/ 
CURS3 
 
Subtract 
 
Km 
(µM) 
 
Kcat 
(s-1) 
 
Reference 
DCS  62% 62% 66% 
Feruloyl-CoA - 0.020 
(Katsuya
ma et al. 
2009a; 
Katsuya
ma et al. 
2009b) 
Malonyl-CoA 8.4 0.011 
CURS1 62%  78% 81% 
Feruloyl-CoA 18 0.018 
Coumaroyl-CoA 189 0.014 
CURS2 62% 78%  81% 
Feruloyl-CoA 4.3 0.007 
Coumaroyl-CoA 89 0.016 
CURS3 66% 81% 81%  
Feruloyl-CoA 2.2 0.003 
Coumaroyl-CoA 2.4 0.006 
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Figure 2: Curcuminoid biosynthetic pathway in Curcuma longa. Cinnamic acid is synthesized from phenylalanine by 
phenylalanine ammonia lyase (PAL) and converted to p-coumaric acid by cinnamate-4- hydroxylase (C4H). Then, 4-
coumarate-CoA ligase (4CL) converts p-coumaric acid to p-coumaroyl-CoA and p-coumaroyl shikimate transferase (CST), p-
coumaroyl 5-O-shikimate 3’-hydroxylase (CS3’H) and caffeoyl-CoA O-methyltransferase (CCoAOMT) converts it to feruloyl-
CoA. p-coumaroyl-CoA and feruloyl-CoA are then converted by diketide-CoA synthase (DCS) to diketide-CoAs by condensation 
with malonyl-CoA. In the end, curcumin synthases (CURSs) catalyze the formation of curcuminoids by condensing the 
diketide-CoAs with p-coumaroyl-CoA and feruloyl-CoA. Depending on the combination, different curcuminoids are produced, 
namely bis-demethoxycurcumin, demethoxycurcumin and curcumin. The route indicated by dashed arrows corresponds to 
a less central phenylpropanoid pathway and may not occur in vivo in C. longa (taken from Rodrigues et al. 2015). 
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 Heterologous production of curcuminoids 
 
Plant secondary metabolites, such as curcuminoids, are accumulated in low quantities, 
are very difficult to isolate and hard to chemically synthesize. Given all the benefits of 
curcuminoids it is necessary to produce these compounds in significant amounts and 
preferentially in an inexpensive way. The heterologous production seems to be the better 
approach for this purpose once. In addiction, heterologous production has the advantage of 
producing pure curcumin as opposed to when it is extracted from turmeric where a 
curcuminoid mixture is obtained.  
Heterologous production in plants, on the first hand, has the advantage of requiring 
the introduction of only one or two genes because the other genes from the phenylpropanoid 
pathway are already present. Moreover, unlike bacteria, they are capable of eukaryotic post-
translational modifications, such as glycosylation. On the other hand, transgenic plants are 
not well accepted in the public domain and genetically modified crops have high costs 
(Streatfield, 2007). However, cultures of plant cells have been used to investigate the 
production of secondary metabolites and plant-cell models carried-out in liquid medium are 
being developed like hairy roots or cell suspension cultures. These models proved to be 
adaptable to large scale reactor. For example, various plants have been used for the 
production of trans-resveratrol constitutively in in vitro conditions (Streatfield, 2007). The 
concentrations of trans-resveratrol that can be produced with the use of plant cell cultures is 
at least equal to that reported as naturally occurring in the plant (Donnez et al., 2009).  
The use of microorganisms has several advantages because they can grow in inexpensive 
substrates, are easier to manipulate and have fast production cycles allowing a faster and 
larger production. Also, microbes usually do not have competing pathways to transgenic 
metabolism making large-scale fermentation and downstream purification easier (Jeandet et 
al., 2012). In addition, the regulations for genetically modified microorganisms are simpler 
than those for plants (Key et al. 2008). 
Mammalian cells represent another alternative host for the curcuminoid synthesis. 
The gene expression in mammalian cells needs a suitable cell line being the most widely used 
the Chinese hamster ovary (CHO). The use of animal cells has the advantage of enabling post-
translational modifications, an accurate folding, an efficient assembly of subunits and the 
secretion of recombinant proteins. Nevertheless, the costs associated with the use of 
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mammalian cells is high and not suitable to scale-up (Khan, 2013). Zhang et al. (2006) used 
unnatural fusing proteins and transformed mammalian cells (human HEK293 kidney cells) to 
produce 0.34 µg/mL (cell volume) of resveratrol. Besides that, no other experiments were 
conducted using animal cells to produce other polyketides.    
 Curcuminoids have already been produced in heterologous hosts. Katsuyama et al. 
(2008) constructed the biosynthetic pathway of curcuminoids in E. coli constituting the first 
study demonstrating the production of curcuminoids in a heterologous organism. PAL from 
the yeast Rhodotorula rubra was the first enzyme of this biosynthetic pathway. The carboxylic 
acids were converted to CoA esters by 4CL from Lithospermum erythorhizon and then in 
curcuminoids by an enzyme called curcuminoid synthase (CUS) from Oryza sativa. CUS is a 
type III PKS able of catalyzing the “one-pot” synthesis of bis-demethoxycurcumin from two 
molecules of p-coumaroyl-CoA and one molecule of malonyl-CoA. It catalyzes both steps 
catalyzed by DCS and CURS in C. longa. The Cys-His-Asn catalytic triad is conserved in CUS and 
this enzyme can also accept cinnamoyl-CoA and feruloyl-CoA as substrates to produce 
dicinnamoylmethane and curcumin, respectively. The architecture of CUS has already been 
studied by Morita et al. (2010), the authors proposed that CUS has a unique down-ward-
expanding active-site architecture allowing the condensation reaction without cyclization. 
Therefore, the use of CUS is a simpler system than the DCS/CURS system. Besides that, PAL 
from R. rubra was shown to possess tyrosine ammonia lyase (TAL) activity, thus tyrosine can 
also be used as precursor. Katsuyama et al. (2008) also overexpressed acetyl-CoA carboxylase 
(ACC) from Corynebacterium glutamicum to increase the intracellular pool of malonyl-CoA. In 
another experiment, phenylpropanoid acids were supplied to a system with only 4CL, CUS and 
ACC genes removing the PAL step to increase the CoA ester concentration. Recombinant E. 
coli produced 91 ± 23 mg/L of bis-demethoxycurcumin, 84 ± 15 mg/L of dicinnamoylmethane, 
and 113 ± 22 mg/L of curcumin.  
 Rodrigues et al. (2015) also produced curcuminoids in recombinant E. coli. The 
researchers tested three different 4CL enzymes from two different organisms and different 
PKS for curcuminoids production (CUS, DCS and CURS). Ferulic acid and/or p-coumaric acid 
were used as precursors. The best results were obtained using 4CL1 from Arabidopsis thaliana 
and DCS and CURS1 from C. longa producing 70 mg/L of curcumin. This system was also tested 
to produce curcuminoids in a bioreactor (Rodrigues, 2014). The amount of produced curcumin 
was much higher than the amount produced of bis-demethoxycurcumin, suggesting that 
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feruloyl-CoA is the preferred substrate which is not in agreement with Katsuyama et al. (2008) 
results. In this work, the 4CL reaction was identified as the limiting step and the bioavailability 
of malonyl-CoA may have affected the amount of curcuminoids produced. More recently, 
Couto et al. (2017) using the same pathway and optimizing the fermentative conditions such 
as culture media or the inducer concentration, produced 353.4 mg/L which represents an yield 
of 95.93 %. Rodrigues et al. (2015) also produced curcumin using tyrosine through the 
production of caffeic acid as an intermediate.  
Zhang et al. (2016) identified a new CURS enzyme from Zingiber officinale. This enzyme 
efficiently accepts 3-(4-hidroxyphenyl) propionyl-CoA to produce tetrahydro 
bisdemethoxycurcumin and also accepts the CoA esters used by CURS from C. longa to 
produce other curcuminoids. Moreover, this enzyme shares 81% identity with CURS1 and the 
highly conserved Cys-His-Asn catalytic triade is also present. In addition, the researchers 
constructed an unnatural fusion protein DCS::CURS and the transformed E. coli cells to 
produce curcumin from feruloyl-CoA. 
More recently, Kim et al. (2017) designed a biosynthetic pathway for de novo synthesis 
of curcuminoids in E. coli. Two pathways were constructed; the first containing 4CL and CUS 
from O. sativa controlled by different promoters and another with the same genes regulated 
by the same promoter. The TAL gene from Saccharothrix espanaensis was also inserted 
together with 4CL and CUS. The engineered E. coli strains produced 0.32 mg/L and 0.09 mg/L 
of bisdemethoxycurcumin, respectively. After that, the curcuminoid productivity was also 
tested using a genetic modified E. coli strain for tyrosine overproduction. The same enzymes 
combination was used and the mutants produced a maximum yield of 6.02 mg/L. Besides that, 
dicinnamoylmethane, other curcuminoid, was produced from phenylalanine cloning PAL from 
A. thaliana in combination with 4CL and CUS from O. sativa. 
 
 Engineering Saccharomyces cerevisiae 
 
The curcuminoids biosynthetic pathway has never been engineered in S. cerevisiae or in 
another organism apart from E. coli. Hereupon, engineering a new yeast to produce 
curcuminoids is an attractive approach. S. cerevisiae was the first eukaryotic organism whose 
genome was fully sequenced (Goffeau et al., 1996) and has been engineered to produce a 
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wide variety of compounds and proteins. Besides, the knowledge on its physiology, genetics 
and fermentations techniques is huge. Among all, S. cerevisiae has a food-grade status 
allowing its use in human nutrition and pharmaceuticals. Secondly, like E. coli, S. cerevisiae is 
easy to grow, manipulate and scale-up, it is well characterized and has been used to produce 
other polyketides. On the other hand, as an eukaryotic organism, it presents unique 
advantages over E. coli that facilitate the functional expression of plant derived genes. S. 
cerevisiae harbors post-translational machinery with intracellular compartments similar to 
plants. In addition, it has an endomembrane system and can functionally express cytochrome 
P450 containing enzymes such as C4H (Koopman et al., 2012). Another advantage is its 
excellent amenability to be manipulated through molecular and synthetic biology techniques, 
taking as example the development of new methods for rapid design and construction of large 
biochemical pathways like the “DNA assembler” (Shao et al. 2009; Yuan and Ching 2015). 
Glycosylation is the most abundant protein modification across all organisms (Larkin and 
Imperiali, 2011). On the other hand, S. cerevisiae has an extensive glycosylation level, referred 
as hyperglycosylation. The hyperglycosylation process may influence the solubility, folding 
and stability of foreign enzymes leading to its inactivation which could represent a problem 
for the heterologous production (Yin et al., 2007). In short, despite some possible difficulties, 
yeast seems to be the ideal host to produce curcuminoids. In the work of Beekwilder et al. 
(2006), resveratrol was produced with p-coumaric acid as precursor in engineered E. coli (16 
mg/L) and in engineered S. cerevisiae (6 mg/L). These results do not imply that the engineered 
E. coli will produce larger amounts of products than the recombinant yeast as both growth 
conditions and strains could be further optimized. Flavonoids and stilbenoids have already 
been produced in engineered S. cerevisiae yielding positive results (Kim et al. 2005; Trantas et 
al. 2009; Zhang et al. 2006). In Table 4 are presented some works on the heterologous 
production of plant phenolic compounds using yeast as the host system.  
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Table 4: Some works on the heterologous production of some phenolic plant compounds using S. cerevisiae as the host 
system. The concentrations are displayed in the same units that are present in the referred works. 
Genes used 
Substrate 
(Concentration) 
Production 
(Concentration) 
Reference 
Rhodotorula glutinis (PAL), 
Helianthus tuberosus (C4H, CPR) 
L-phenylalanine 
(1 mM) 
p-coumaric acid 
(498 µM) 
(Vannelli et al., 2007) 
Populus trichocarpa (4CL) 
Vitis vinifera (RS) 
p-coumaric acid 
(10 mg/L) 
Resveratrol (1.38 µg/L) (Becker et al., 2003) 
Arabidopsis thaliana (4CL1) 
Arachis. hypogaea (STS) 
p-coumaric acid 
(16 mg/L) 
Resveratrol (3.1 mg/L) (Shin et al, 2011) 
R. toruloides (PAL) 
A. thaliana (C4H and 4CL1) 
A. hypogaea (STS) 
Tyrosine 
(2 mM) 
Resveratrol (5.8 mg/L) (Shin et al., 2012) 
Rhodosporidium toruloides (PAL) 
A. thaliana (4CL) 
Hypericum androsaemum (CHS) 
Tyrosine and 
phenylalanine 
(65 mg/L each) 
Naringenin (7 mg/L) (Jiang et al., 2005) 
 
  Optimization of the curcuminoid biosynthetic pathway  
1.5.1 From amino acids to coenzyme A esters 
 
S. cerevisiae lacks the CoA esters, i.e. the starter substrates needed to produce 
curcumin. In addition, phenylalanine and tyrosine, naturally produced amino acids, which are 
converted into phenylpropanoic acids, and then in CoA-esters, are not produced in sufficient 
amounts representing a limiting step (Jiang et al., 2005; Kang et al., 2012). The aromatic amino 
acids biosynthesis is a branched pathway regulated at transcriptional, translational and 
allosteric levels. At allosteric level, the effector molecules are the end products, for example 
the reaction catalysed by chorismate mutase (the last common step in tyrosine and 
phenylalanine biosynthesis) is feedback-inhibited by tyrosine, but curiously no effect of 
phenylalanine is known (Schmidheini et al., 1990). Despite amino acids or phenylpropanoids 
can be supplemented to the culture medium, the use of tyrosine/phenylalanine 
overproduction strains represent the cheapest solution for this problem and has already been 
used. For instance, Koopman et al. (2012) using a mutated strain of S. cerevisiae with feedback 
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inhibition-resistance to produce naringenin, obtained larger amounts of the product 
comparatively with the wild type strain. Supplementing the media with curcumin precursors, 
ferulic acid or phenylalanine, makes the process expensive for industrial applications, 
therefore the development of strains capable of converting glucose or other simple carbon 
sources to curcumin represents also an important strategy for engineering processes. Li et al., 
(2015) constructed a pathway for de novo biosynthesis of resveratrol from glucose generating 
2.73 + 0.05 mg/L of the polyphenol. In another experiment, to improve the flux towards 
aromatic amino acids, the researchers developed a feedback-inhibition resistant strain 
overexpressing chorismate mutase and 3-Deoxy-D-arabinoheptulosonate 7-phosphate 
(DAHP) synthase resulting in 4.85 + 0.31 mg/L resveratrol produced from 30 g/L glucose. 
Comparing these results with the resveratrol production yields shown in Table 4, the de novo 
production seems to be a very attractive approach for the polyphenol production in yeast 
mainly for industrial applications. 
PALs from some plants, like Zea mays also have tyrosine ammonia lyase (TAL) activity, 
converting tyrosine to p-coumaric acid, the substrate of 4CL. PAL enzymes that allow p-
coumaric acid to be produced without requiring the C4H step represent an advantage to 
prokaryotes because C4H is a membrane bound cytochrome P450-dependent (Rösler et al., 
1997). Some authors reported their findings in bacterial TALs. TALs from Rhodobacter 
spaheroids and Rhodobacter capsulatus showed a clear preference for tyrosine instead of 
phenylalanine (Berner et al., 2006). In some works, using S. cerevisiae as the host for the 
production of stilbenoids and flavonoids, PAL and also C4H (this enzyme can be expressed in 
yeast due to the cytochrome P450 reductase activity) were used. C4H from A. thaliana and 
Glycine max were successfully cloned and expressed in S. cerevisiae, but its activity remains a 
rate limiting step since the endogenous cytochrome P450 reductase activity is not enough to 
support its expression (Trantas et al., 2009; Yan et al., 2005).  
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1.5.2 4-Coumarate-CoA reaction 
 
The 4CL enzymes family catalyses the conversion of p-coumaric acid, ferulic acid and 
caffeic acid to the respective CoA esters. 4CL has been shown to occur in the form of multiple 
isoenzymes with distinct substrate affinities (Ehlting et al., 1999). Much of the work in the 
heterologous production of flavonoids and stilbenoids in S. cerevisiae used 4CL from G. max 
or A. thaliana (Table 5 and Table 6). This seems to be the better approach since these 
organisms are the best characterized in the plant kingdom. For example, A. thaliana possesses 
four isoforms of 4CL (At4CL1, At4CL2, At4CL3 and At4CL4). From the results of expression 
patterns and phylogenetic similarity, At4CL3 is suggested to play a role in ﬂavonoid 
biosynthesis, while At4CL1 and At4CL2 are presumed to be involved in lignin production. 
At4CL4 exhibits a substrate preference to ferulic acid and sinapic acid over p-coumaric acid 
(Hamberger and Hahlbrock, 2004; Saito et al., 2013) which may be an advantageous strategy 
for the heterologous production of curcumin. Li et al. (2015) also tested if the use of different 
A. thaliana 4CL isoforms (4CL1 and 4CL2) would have an impact on the production of 
resveratrol by the engineered yeasts. The results confirmed that 4CL1 consistently resulted in 
slightly higher resveratrol titters than 4CL2 confirming the high activity of 4CL1 when p-
coumaric acid is the substrate which agrees with the results obtained by Ehlting et al. (1999). 
 
Table 5: Kinetic parameters of the three isoforms of 4CL from Glycine max 
Organism Abbreviation Substract Km (mM) Reference 
G. Max 
Gm4CL1 
p-coumaric acid 0.05 
(Lindermayr et 
al., 2003) 
caffeic acid 0.081 
ferulic acid 0.004 
Gm4CL2 
p-coumaric acid 0.042 
caffeic acid 0.013 
ferulic acid 0.14 
Gm4CL3 
p-coumaric acid 0.009 
caffeic acid 0.05 
ferulic acid 3.1 
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Table 6: Kinetic parameters of the three isoforms of 4CL from Arabidopsis thaliana 
Organism Abbreviation Substract Km (mM) Reference 
 
A. thaliana 
At4CL1 
p-coumaric acid 0.038 
(Ehlting et al., 
1999; Hamberger 
& Hahlbrock, 
2004) 
caffeic acid 0.011 
ferulic acid 0.199 
At4CL2 
p-coumaric acid 0.252 
caffeic acid 0.020 
ferulic acid No cat. 
At4CL3 
p-coumaric acid 0.023 
caffeic acid 0.374 
ferulic acid 0.166 
At4CL4 
p-coumaric acid 0.432 
caffeic acid 0.186 
ferulic acid 0.026 
 
 
Jiang et al., (2005) designed an engineered S. cerevisiae for the production of 
flavonoids. For this purpose, the researchers cloned PAL from Rhodosporidium toruloides 
(RtPAL) (this PAL also shows TAL activity), 4CL from A. thaliana and chalcone synthase (CHS) 
from Hypericum androsaemum in a S. cerevisiae pad1 knockout strain. This gene encodes for 
phenylacrylic acid decarboxylase (PAD), an enzyme responsible for the reduction of cinnamic 
acid and p-coumaric acid. Using this engineered strain 5.8 mg/L of naringerin (flavonoid 
derived from tyrosine) and traces of pinocembrin (flavonoid derived from phenylalanine) were 
produced. Besides, to ensure the activity of each enzymatic step, the authors constructed 
yeast strains expressing each gene. To analyse the RtPAL activity, the concentrations of 
cinnamic acid and p-coumaric acid were measured in yeast expressing only RtPAL after 
induction. In order to analyse the At4CL activity, the crude protein mixture was extracted and 
the production of p-coumaroyl-CoA was followed by ultraviolet-visible spectroscopy. p-
Coumaroyl-CoA was produced in yeasts transformed with At4CL and RtPAL and in yeasts 
transformed only with At4CL. Besides naringenin and pinocembrin, other flavonoids by-
products were also quantified. The researchers concluded that the At4CL also accepts 
cinnamic acid but with low efficiency due to the lower level production of pinocembrin. The 
lower level of flavonoids production derived from tyrosine was mainly due to the low level of 
p-coumaric acid production which led the authors to believe that there could be other 
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enzymes in addition to PAD capable of degrading the p-coumaric acid. Since A. thaliana C4H 
was previously successfully expressed in S. cerevisiae (Pompon et al., 1996), the researchers 
hypothesized that the introduction of C4H would compete with PAD and/or the unknown 
endogenous yeast enzymes that degrade cinnamic acid and redirect the carbon ﬂux to p-
coumaric acid, thus enhancing the production of naringenin.  
The choice of the right enzymes combinations is a key step to produce heterologous 
compounds like curcumin in yeast. The utilization of enzymes with multiple substrate affinities 
like 4CL and CURS, enzymes that reduce the number of reactions required such as TAL, as well 
as the deletion or overexpression of genes that may hinder the production process represent 
all strategies of optimization at the genetic level which should be considered. 
 
1.5.3 Ferulic acid availability 
 
Ferulic acid is the precursor of curcumin. In S. cerevisiae, ferulic acid can be 
decarboxylated and converted in 2-methoxy-4-vinylphenol by ferulic acid decarboxylase (FDC) 
as a detoxification process (Huang et al., 1993; Mukai et al., 2010). FDC is encoded by fdc1 and 
the utilization of a strain with fdc1 knockout could represent an optimization method for the 
production of curcumin in S. cerevisiae. The development of knockout strains has already 
proved to be useful in the synthesis of polyphenols in S. cerevisiae.  Shin et al, (2011) produced 
resveratrol using a pad1 knockout S. cerevisiae strain. The deletion of PAD1 gene prevented 
the utilization of p-coumaric acid by yeast. Nevertheless, the development of a fdc1 knockout 
strain may be an interesting strategy because a possible ferulic acid consumption could be 
prevented and it can be all used for curcumin synthesis.  
1.5.4 Synthetic biology techniques 
 
For metabolic engineering purposes, linking genes together to generate a functional 
fusion protein offers an attractive strategy for increasing product yields. The use of fusion 
proteins also reduces the number of vectors in a heterologous expression system, which 
simplifies the reconstitution of metabolic pathways. In addition, protein-protein interactions 
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may increase metabolic efficiency either by channelling intermediates between enzymes or 
by locating two active sites in a close proximity. This hypothesis was tested by Zhang et al., 
(2006). The authors constructed a translational fusion protein of 4CL from A. thaliana and 
stilbene synthase (STS) from Vitis vinifera (4CL::STS) for the resveratrol biosynthesis in 
transformed S. cerevisiae. The fusion protein consisted of the 4CL with its stop codon replaced 
by a three-amino acid linker, followed by STS. The yeasts transformed with 4CL::STS fusion 
protein increased resveratrol production by up to 15-fold compared to transformants 
coexpressing 4CL and STS. More recently, Wang and Yu (2012) used a synthetic scaffolds 
strategy to produce resveratrol in yeast with the same enzymes and observed a 5.0-fold 
improvement over the non-scaffold control, and a 2.7-fold increase over the previous 
reported with fusion protein. This work demonstrated that the synthetic scaffolds can be used 
for the optimization of engineered metabolic pathways. Zhang et al., (2016) already produced 
an unnatural DCS and CURS fusion protein for heterologous production of curcuminoids in E. 
coli. The researchers used DCS from C. longa and the recently identified by CURS from Z. 
officinale. The yield of curcuminoids produced by DCS::CURS fusion protein was higher 
relatively to that produced by E. coli transformed with DCS and CURS. This was the first study 
in which fusion proteins were used to produce curcuminoids. 
Codon optimization must be a strategy to consider, due to the existence of rare codons 
in heterologous genes, the expression of those genes can lead to translational errors, 
frameshifting events, stalling or premature translational termination, especially when 
transcripts containing rare codons accumulate in large quantities (McNulty et al., 2003). 
Codon optimization has been shown to improve activities of pathway enzymes relative to the 
ones from native genes and it is now a commonly used technique in the construction of 
heterologous pathways (Redding-Johanson et al., 2011). Wang et al. (2011) showed that 
codon optimization in S. cerevisiae drastically improved the production of resveratrol in vivo. 
In this work it was also demonstrated that expression of a non-specific transporter was 
important to increase the resveratrol productivity. Curcumin and resveratrol, like other 
polyphenols, accumulate in plant vacuoles (Dixon and Paiva, 1995) and the transportation of 
these compounds from vacuoles is not fully understood. Wang et al. (2011) also expressed the 
arabinose-H+ transport protein (AraE) in the engineered yeast. The transporter greatly 
improved the resveratrol synthesis indicating that AraE may increase resveratrol permeability 
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through lipid membranes when resveratrol levels are elevated over a threshold. Maybe a 
similar strategy could be useful to increase the curcuminoids production. 
 
1.5.5 Malonyl-CoA availability 
 
In the curcuminoids production it is necessary one molecule of malonyl-CoA to obtain 
the final product. However, malonyl-CoA inside the cell is at low concentrations which could 
represent a limiting step in the heterologous production of curcuminoids. Malonyl-CoA is 
naturally synthesized by ACC (catalyses the carboxylation of acetyl-CoA to malonyl-CoA) in 
microorganisms but it is used for the production of fatty acids and phospholipids, leaving only 
a very limited amount available for the production of secondary metabolites (Takamura and 
Nomura, 1988). The engineering of the microbial host to achieve metabolic balance between 
the need for malonyl-CoA for growth and secondary metabolite production is essential. In 
bacteria and plant cells, malonyl-CoA can be generated through the condensation of malonic 
acid. Studies on overexpression of a plant malonyl-CoA synthase in S. cerevisiae resulted in a 
1.6 fold increase in lipid content, which suggested the increase of the malonyl-CoA pool (Tang 
et al., 2015). Engineering microorganisms with ACC genes from other organisms or changing 
the promoter of ACC to a strong constitutive promoter are strategies that have been used to 
develop engineered strains overproducing ACC (Miyahisa et al., 2005; Wattanachaisaereekul 
et al., 2008). ACC in yeast is subject to inactivation via phosphorylation by a kinase, called 
sucrose non-fermenting protein kinase (SFN1). Studies demonstrate that site mutations in 
ACC could enhance the supply of malonyl-CoA by inhibiting phosphorylation of ACC (Shi et al., 
2014). Since ACC belongs to the family of biotin dependent carboxylases, the efficiency of ACC 
biotinylation controls its activity, and it has been reported that the reduced level of this 
vitamin affects the synthesis of fatty acids suggesting its role in malonyl-CoA production 
(Suomalainen and Keränen, 1963). For instance, to increase the pool of malonyl-CoA for 
resveratrol production in an engineered yeast, Shin et al. (2012) elevated the expression level 
of ACC1 transcript by replacing the native promoter for GAL promoter. The overexpression of 
the ACC1 gene resulted in 1.3-fold increase in resveratrol concentration.  
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 Heterologous production in Saccharomyces cerevisiae  
1.6.1 Culture media 
 
The use of a proper culture medium may be the key point to obtain large quantities of 
the desired product. The optimization of the fermentation conditions should be an aspect to 
consider to produce curcumin in yeast. Sydor et al. (2010) studied the resveratrol synthesis 
from p-coumaric acid in S. cerevisiae expressing the At4CL1 and STS from V. vinifera growing 
in rich (YPD) or synthetic medium (SD) supplemented with 5 mM of p-coumaric acid. Yeasts 
grown in SD medium produced 6 mg/L of resveratrol, while in YPD medium 391 mg/L were 
produced. Therefore, the authors concluded that resveratrol productivity can be increased by 
fermentation in YPD instead of SD medium because higher amounts of biomass are obtained. 
Curcuminoids have never been produced in S. cerevisiae so there is no specific information on 
the culture media that can favour its production. The YPD medium is generally used in the 
production of other polyketides. However, the use of rich media has the disadvantage of not 
allowing the selection of transformants when auxotrophic markers are used. Rice bran pitch, 
an industrial waste obtained from rice bran in the production of rice oil and rich in ferulic acid, 
was used by Katsuyama et al. (2008) to produce curcumin in E. coli yielding 57± 21 mg/L of 
curcumin. 
 
1.6.2 Vectors and promoters 
 
In order to increase the productivity many factors must be considered including 
optimizing the pathway flux, using gene deletion or overexpression, as mentioned, as well as 
reducing the toxic intermediates and balancing the stress on the cell. Thereupon, the choice 
of the right expression vector is a key step in pathway engineering. Most expression plasmids 
allow the expression of only one gene. However, for the expression of an entire metabolic 
pathway, it is desirable to express more than one gene per plasmid unit. Different expression 
systems, such as yeast integrative plasmids (YIps) for integration of the desired gene into the 
yeast genome or yeast episomal plasmids (YEps) for high copy number expression, have been 
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designed and developed. The use of plasmids imposes a metabolic burden on the host that 
usually reduces the growth rate of the cell. The two-step fermentation is a commonly used 
strategy to compensate this metabolic burden. The vector copy number is very important 
because not always a high copy number is desired. High copy plasmids rely the 2µ origin of 
replication which allows about 30 copies per cell (Mumberg et al., 1995). This kind of plasmid 
allows a strong gene expression which can cause an excessive burden resulting in instability 
of the construct. The low copy plasmids have an autonomously replication sequence paired 
with centromere to allow stable maintenance at very low copy (Parent et al., 1985). Low copy 
plasmids provide a more stable expression platform, but with lower gene expression. 
However, when YEps is used a selective pressure is required. YIps provide the most stable 
platform and does not require continuous selective pressure but the expression levels are 
lower. Jordan and Nash (2015) studied the plasmid loss rate in S. cerevisiae harbouring YEpd 
in the absence of selective pressure. The authors concluded that yeast maintain the plasmids 
much longer than expected suggesting that growth in non-selective medium may be a viable 
method. Usually, the selective pressure is exerted by an auxotrophic marker which makes 
impossible the use of rich media. Sydor et al. (2010), mentioned above, used 2µ plasmids with 
an antibiotic resistance marker making possible the use of rich media. 
The choice of the promoter controlling the expression of the pathway genes is also 
very important. S. cerevisiae has a set of well characterized promoters with different 
expression levels (Partow et al., 2010). These promoters can be grouped by the type of 
control, i.e. constitutive and inducible. Inducible promoters have the advantage of being able 
to control enzyme levels but have the disadvantage that the inducer molecules for these 
systems have known pleiotropic effects as also the cells may consume the inducers, galactose 
for instance, decreasing the gene expression (Mumberg et al., 1995).  
 
 Curcumin extraction, quantification and characterization 
 
The extraction is an essential step to obtain compounds produced in heterologous 
organisms, because if the extraction process is not efficient the whole process is 
compromised. Curcuminoids are purified by solvent extraction in turmeric and this method 
was also used in the works in which the curcuminoids were produced in E. coli. After the 
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culture is adjusted to pH 3.0 with HCl, the extraction of curcuminoids is proceeded with equal 
volume of ethyl acetate and then concentrated by evaporation (Katsuyama et al., 2007). In a 
study performed by Kulkarni et al. (2012), several solvents with varying polarities were 
evaluated to extract curcuminoids in turmeric. The extraction with methanol yielded the 
greater amounts of curcuminoids followed by extraction with sodium acetate. The lysis of the 
cells before extraction was found to increase the amount of the extracted product, since the 
produced curcuminoids can remain inside the cells. 
Many methods for the quantiﬁcation of the curcuminoids have been reported 
including high-performance thin-layer chromatography (HPTLC) (Ansari et al., 2005), high-
performance liquid chromatography (HPLC) (Jayaprakasha et al., 2002), and mass 
spectrometry (MS) (Inoue et al., 2007). These methods allow both the quantification and 
characterization of the various curcuminoids. 
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2 OBJECTIVES 
 
The main goal of this work was to design, construct and validate a biosynthetic 
pathway composed by genes from different plants to produce curcumin from ferulic acid in 
an engineered S. cerevisiae. Other specific aims included: 
- Evaluation of S. cerevisiae behaviour in the presence of different concentrations of 
ferulic acid; 
- Design, construction and validation of three different curcumin biosynthetic 
pathways using molecular and synthetic biology techniques;  
- Evaluation of the efficiency of diverse curcumin extraction methods; 
- Development of a fdc1 gene knockout S. cerevisiae strain using CRISPR-Cas9 
technology; 
- Evaluation of S. cerevisiae mutant in curcumin production. 
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3 MATERIALS AND METHODS  
 Strains, plasmids and genes 
 
E. coli NZY5α (NZYTech) competent cells were used for molecular cloning, vector 
propagation and storage. S. cerevisiae CEN.PK2-1C and S. cerevisiae Y02123 were used as 
hosts for genes expression and curcumin production (relevant genotype information provided 
in Annex A). Moreover, S. cerevisiae CEN.PK2-1C was also used for curcumin production after 
knockout of fdc1 gene (Section 3.8). 
The vector used for the pathway construction was pSP-GM1, kindly provided by Jens 
Nielsen, Chalmers University of Technology, Sweden (Addgene plasmid # 64739) (Chen et al., 
2012). This shuttle vector has 7404 bp, possesses the ampicillin resistance gene (for selection 
in E. coli), the URA3 gene (for selection in S. cerevisiae) and two S. cerevisiae constitutive 
promoters (TEF1 (3’ -> 5’) and PGK1 (5’ -> 3’) with the respective terminators (ADH1 and CYC1). 
Another vector herein used was the pCRCT (Addgene plasmid # 60621) (Bao et al., 2015) for 
CRISP-Cas9 method. This plasmid holds the ampicillin resistance gene and the URA3 gene, and 
also possesses the LacZ gene for blue and white screening and all the machinery necessary for 
CRISPR-Cas9 namely the iCas9 gene and the tracrRNA. The maps of the commercial vectors 
are available in Figure B1 and Figure B2 in Annex B. All the plasmids used and constructed in 
this work are displayed in Table B1 in Annex B.  
The genes At4CL, Le4CL and CUS and the TDH3 promoter were obtained from plasmids 
previously constructed (Rodrigues, 2014; Rodrigues et al., 2015). DCS and CURS1 genes codon-
optimized for S. cerevisiae were synthetized and cloned into pNZY29 vector by NZYTech. These 
plasmids were transformed into E. coli NZY5α cells for propagation and storage. The codon 
optimized sequences are provided in Annex C. The double strand DNA fragment used for fdc1 
knockout using CRISPR-Cas9 (gBlock) was synthetized by Integrated DNA Technologies (IDT).  
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 Chemicals, culture media and microbial growth conditions 
 
Standard reagents were used to prepare the culture mediums: LB broth and SOC broth 
(NZYTech); YPD media (3.3% (p/v) Yeast extract (Panreac Applichem), 2% (p/v) peptone 
(Fluka), 2% (p/v) glucose (Acros Organics) and 0.7% (p/v) YNB minimal media without amino 
acids (Sigma) with also 2% (p/v) of glucose as carbon source. Ampicillin (AppliChem) was used 
at a final concentration of 100 µg/mL and the required amino acids (L-histidine and L-leucine 
(Fisher), L-tryptophan (Sigma) and L-methionine (AppliChem)) at a final concentration of 25 
µg/mL. Uracil (URA) (Sigma) was used with a final concentration of 50 µg/mL. The agar plates 
contained 20 g/L of agar (Liofilmchem). Glycerol (Himedia) solution 70% (v/v) was used for 
culture storage. 
E. coli cell cultures were cultivated at 37oC and 200 rpm. Transformants were selected 
in LB solid medium supplemented with ampicillin.  S. cerevisiae was grown at 30 oC and 250 
rpm, and the transformants were selected in YNB solid media supplemented with the required 
amino acids lacking uracil for selection (YNB -URA). For plasmid curing in yeast, YNB plasmid 
curing plates contained 5 g/L of 5-fluoroorotic acid (5-FOA) (Sigma). 
For yeast transformation, 1 M lithium acetate (Sigma), 50% (p/v) polyethylene glycol 
3000 (PEG 3000) (Sigma) and 10 mg/mL deoxyribonucleic acid low molecular weight from 
salmon sperm (ssDNA) (Sigma) solutions were prepared. Ferulic acid (Acros Organics) diluted 
in dimethyl sulfoxide (DMSO) (Fisher Scientific) was used as substrate for curcumin 
production. Curcumin (95 % purity) (Acros Organics), 2-Methoxy-4-vinylphenol (Alfa Aesar), 
methanol (Fisher Scientific), acetonitrile (Fisher Scientific), trifluoracetic acid (TFA) (Fluka), 
phosphoric acid (Sigma), ethanol (Fisher Scientific) and ethyl acetate (Fisher Scientific) were 
used for the curcumin extraction process and for high-performance liquid chromatography 
(HPLC) analysis. 
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 Pathway and primer design  
 
For curcumin production in yeast, three different pathways were designed using pSP-
GM1 vector. In two of the pathways CUS gene from O. sativa was cloned with 4CL from distinct 
organisms (A. thaliana and L. erythrozium). In the third pathway, DCS and CURS1 codon 
optimized for S. cerevisiae and 4CL1 from A. thaliana were used. 
The primer design considered the insertion of the same restriction sites used to cut the 
plasmid between the respective promoter and terminator as well as the insertion of a 
ribosome recognition site (5’- AAAAAA - 3’) before the starting codon of each gene. Two 
distinct enzymes which originate cohesive ends were used for a single insert to ensure the 
insertion of the gene with the right orientation. All the primers and plasmids are displayed in 
Table D1 (Annex D) and Table B1 (Annex B), respectively. The primers used for colony PCR 
and sequencing are described in Table D2.   
Since pSP-GM1 only has two multiple cloning sites, and for the third pathway it is 
necessary to insert three genes, the TDH3 promoter and synthetic terminator 27 were also 
cloned to express a third gene (CURS1) in pSP-GM1. For that purpose, the promoter TDH3 was 
first inserted in pSP-GM1_DCS_4CL forming the plasmid pSP-GM1_DCS_4CL_TDH3. Note that, 
TDH3_REV primer, besides the AvrII sequence, possesses also the SphI sequence which 
allowed to insert the SphI restriction site in the plasmid pSP-GM1_DCS_4CL_TDH3 right after 
the TDH3 sequence. Afterwards, the SphI site was used to clone the CURS1 gene. Besides, the 
reverse primer for CURS1 possessed the sequence of the synthetic terminator 27 allowing the 
construction of a cassette composed by the gene and the regulatory region. This strategy can 
be visualized in Figure 3.  
 
 
Figure 3: Strategy used to insert the third gene in pSP-GM1_DCS_At4CL_CURS1: A: pSP-GM1_DCS_At4CL with AscI and 
AvrII sites highlighted; B: TDH3 promoter and SphI restriction site insertion forming pSP-GM1_DCS_At4CL_TDH3; C: CURS1 
gene and synthetic terminator 27 insertion forming pSP-GM1_DCS_At4CL_CURS1. 
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 Plasmid construction 
 
Plasmid DNA (pAt4CL, pLe4CL, pDCS, pCURS, pCUS, pSP-GM1 and pCRCT) was extracted 
using NucleoSpin® Plasmid extraction kit (Machinery-Nagel) from an overnight growth of E. 
coli culture.  
The genes were PCR-amplified using the homonymous primers and Phusion DNA 
Polymerase (Thermo) and homonymous plasmids as DNA template (PCR conditions displayed 
in Table 7) and purified from agarose gel using NucleoSpin® Gel and PCR Clean-up (Machinery-
Nagel). DNA Electrophoresis was performed with a 0.7 % (p/v) agarose (Fisher Scientific), 
during 30 min at 90 V. A loading dye containing bromophenol blue and glycerol was loaded 
with the sample and NZYDNA ladder III (NZYTech) was used as a marker. Thiazole orange 
(Sigma) was used as DNA dye. The bands were visualized using ChemiDoc Imaging System (Bio-
Rad). The plasmid DNA and genes were quantified by NanoDrop 1000 (Thermo).  
 
 
Table 7:  PCR conditions used to amplify the genes and TDH3 promoter using Phusion High-Fidelity DNA polymerase 
 
 
 
Afterwards, the plasmid DNA and the genes were digested with the respective 
restriction endonucleases (Thermo) for 3 h at 37oC and purified using the extraction kit. The 
plasmid DNA was first run in agarose gel after digestion and then purified. Then, the fragments 
were ligated using T4 DNA ligase (Thermo), at room temperature for 1 h. E. coli NZY5α 
competent cells were chemically transformed by heat-shock method, according to the 
instructions provided by NZYtech. The constructed plasmids were verified by colony PCR using 
Cycling step At4CL Le4CL CUS DCS At4CL_2 TDH3 CURS1 
Initial denaturation  98 oC, 30 s 
Denaturation  
30x 
98 oC, 5 s 
Annealing  
63 oC, 
20 s 
63 oC, 20 
s 
66 oC, 20 
s 
56 oC, 
20 s 
62 oC, 20 s 
58 oC, 20 
s 
58 oC, 20 
s 
Extension  
72 oC, 
52 s 
72 oC, 58 
s 
72 oC, 37 
s 
72 oC, 
36 s 
72 oC, 52 s 
72 oC, 31 
s 
72 oC, 38 
s 
Final extension  72 oC, 5 min 
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the specific primers for pSP-GM1 and KAPA Taq DNA polymerase (KAPA Biosystems). Next, 
the plasmids were digested and further confirmed by sequencing (GATC Biotech, Konstanz, 
Germany) (Information about colony PCR conditions present in Table E1 and Table E2 in 
Annex E). In all cases the engineered strains were cryopreserved at -80oC in glycerol. 
 Yeast transformation 
 
All the constructed plasmids were first transformed in E. coli NZY5α cells using heat-
shock method to ensure the plasmid propagation as already mentioned. After that, plasmid 
DNA was extracted using the purification kit from an overnight culture grown in LB 
supplemented with ampicillin. Next, the vectors pSP-GM1_Le4CL_CUS, pSP-GM1_At4CL_CUS 
and pSP-GM1_DCS_At4CL_CURS were transformed into the yeast strains using lithium 
acetate/single-stranded carrier DNA/PEG method (Gietz, 2014). Some modifications were 
added to the method in order to improve the transformation efficiency: the transformation 
mix was maintained in ice for 30 min before the heat-shock and after the heat-shock the cells 
were inoculated with 1 mL YPD and maintained at 30oC, 200 rpm during 1 h. The transformants 
were plated in selective medium (YNB-URA) and the plates were maintained at 30oC during 
approximately 3-4 days. Afterwards, the colonies were inoculated in 5 mL of liquid selective 
medium and grown overnight at 30oC, 200 rpm. Then, 2 mL of the culture was stored at -80oC 
in glycerol and YNB -URA agar plates were prepared using the streak technique allowing to 
obtain multiple colonies from a single transformant for further utilization.  
 
 Batch fermentation 
 
A single colony was used to prepare a 5 mL pre-culture, in 50 mL falcon tubes. Rich YPD 
medium was used for wild-type strains and synthetic defined YNB medium without uracil (to 
ensure the selective pressure) was used for the engineered strains. When the pre-culture 
reached an OD600nm > 1, 1 mL of the pre-culture was used to inoculate 50 mL of media in 250 
mL shake flasks. The optical density was measured using spectrophotometer UV-3100OC 
(VWR). 
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3.6.1 Dry weight calibration 
 
S. cerevisiae CEN.PK2-1C was grown in 50 mL YNB broth. The fermentation was 
maintained until a constant OD600nm was reached. At this point, successive dilutions of the 
sample were measured. Five membranes (porosity 0.2 µm) (GE Healthcare) were weighed. 
Three membranes were used to filtrate 5 mL of culture, followed with a wash with 5 mL of 
water. The other two membranes were used as control being only filtered 5 mL of water. The 
filters were dried in the microwave for 10 min at 150 W and placed in the drying oven at 55oC 
for more 15 min. After that, the filters were weighed and the dry weight biomass calculated 
by the difference in weight before and after fermentation. This process allowed to construct 
the calibration curve of biomass concentration (g/L) versus OD600nm present in Figure F1 in 
Annex F.  
3.6.2 Ferulic acid toxicity assay 
 
To evaluate if ferulic acid influences yeast growth a toxicity assay was performed. For 
this purpose, four 250 mL flasks with 50 mL YNB media (2% (w/v) glucose) supplemented with 
the required nutrients were inoculated with 1 mL of the grown pre-culture of S. cerevisiae 
CEN.PK2-1C wild-type. The fermentation was carried at 30 oC and 250 rpm. Samples were 
taken at certain time points:  6h, 24h and 48h to measure the OD600nm and for further HPLC 
analysis. When the OD600nm reached a value of 0.2, ferulic acid diluted in DMSO was added to 
the culture media at different final concentrations: 0.5 mM, 1 mM, 2mM and 5mM. The 
fermentation process was maintained during 48 h. 
 
3.6.3 Curcumin production 
 
Yeast strains transformed with pSP-GM1_At4CL_CUS, pSP-GM1_Le4CL_CUS, 
pSPGM1_DCS_4CL_CURS1 were tested for curcumin productivity. For this purpose, 1 mL of 
the pre-inoculum (2% of the final volume) was inoculated in 50 mL of YNB -URA with 2% (w/v) 
glucose in 250 mL shake flasks. A solution of ferulic acid diluted in DMSO was prepared and 
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different substrate concentrations were added to the media 0.08 mM (16 mg/L), 0.4 mM (80 
mg/L), 0.8 mM (160 mg/L) and 2 mM (388.3 mg/L). The fermentation process was 
accompanied for 6 days at 30oC and 250 rpm and 2 mL samples were taken every 24 h to 
measure the OD600nm. The curcumin production was confirmed by the yellow colour formation 
in the culture media. A representative scheme of the fermentation process is shown in the 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Curcumin extraction 
 
To extract curcumin, three different methods were tested. In the first one, yellow 
cultures (50 mL) were spun down (13000 g for 2 min) and the supernatant (culture media) was 
removed. The yellow biomass, suggesting that curcumin remains inside the cells, was re-
suspended in 1 mL of methanol and vortexed vigorously for 2 min. After that, the liquid phase 
was separated from the biomass and placed in a clean 2 mL centrifuge tube and the samples 
were concentrated by evaporation of the methanol in a fume hood.  
The extraction was also tested using ethanol 70 % (v/v) to break the cells. For that, 8 mL 
of the culture media was removed, the biomass was suspended in 1 mL of the ethanol solution 
Figure 4: General scheme of the fermentation process: A: A single colony was picked from a YNB- URA transformation plate 
to prepare a 5 mL pre-culture in YNB selective media; B: Pre-inoculum growth at 30 oC until an OD 600 nm >1 was reached; C: 
1 mL of the pre-inoculum was inoculated in 50 mL selective media, 2 mL cryopreserved at -80 oC and streak plate to isolate 
single colonies; D: The fermentation was carried at 30 oC, 250 rpm in the presence of ferulic acid. The yellow colour formation 
confirmed the curcumin production. Colours are not representative.    
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and vortexed during 10 min. Afterwards, ethanol was evaporated and curcumin was extracted 
from the remaining water with 500 µL of ethyl acetate and concentrated by evaporation.  
In the third method glass beads were used to break the cells. For that, FastPrep®-24 (MP 
Biomedics) cell disruptor was used. Lysis tubes with 1 mL of culture together with glass beads 
(diameter: 0.5 mm) were prepared. The program was set for 60 m/s during 1 min followed by 
1 min on ice. The process was repeated three times. Next, the liquid phase and the glass beads 
were separated by centrifugation. Curcumin was extracted with 500 µL ethyl acetate from the 
liquid phase and concentrated by evaporation. 
Afterwards, in the three extraction approaches, the dried curcumin was re-suspended 
in 300 µL of acetonitrile for further HPLC analysis. 
 
3.7.1 HPLC analysis 
 
HPLC was used to quantify the produced curcumin as well as to quantify the 
consumption of ferulic acid and the formation of 2-methoxy-4-vinylphenol during the 
fermentation process. The chromatographic system was composed by Shimadzu Nexera-X2 
(Shimadzu Corporation, Kyoto, Japan) (CBM-20A system controller, LC-30AD pump unit, DGU-
20A 5R degasser unit, SPD-M20A detector unit, SIL-30AC autosampler unit, CTO-20AC column 
oven) system and the column was a Platinum 100 C18 EPS (3 μm, 150 mm × 4.6 mm) (Dr. 
Maisch). For curcumin detection and quantification mobile phase A was composed of water 
with 0.1% of TFA and the mobile phase B was composed of acetonitrile. A gradient of 40-43% 
acetonitrile for 20 min was used at a flow-rate of 1 mL/min and curcumin was detected at 425 
nm and in a retention time of 15.5 min. For ferulic acid and 2-methoxy-4-vinylphenol 
quantification, mobile phase A was composed of water with 1% of phosphoric acid and the 
mobile phase B was methanol with 1% phosphoric acid. A ratio 60:40 (water:methanol) was 
used at a flow-rate of 1 mL/min for 10 min. Ferulic acid and 2-methoxy-4-vinylphenol were 
detected at 310 nm and 240 nm and in a retention time of 2.4 min and 6.7 min, respectively.   
 
 
 
Production of curcumin by an engineered Saccharomyces cerevisiae 
35 
 Gene deletion  
3.8.1 CRISPR-Cas9 target site selection and sequence design  
 
The sequence that directs the Cas9 protein to cleave the target DNA sequence (fdc1 
gene) was ordered as a gBlock (IDT) as described in Figure 5. In this case, CRISPR technology 
was used to cause an 8 bp deletion in fdc1 gene. The 8 bp deletion causes an alteration in the 
gene open reading frame putting a stop codon in frame resulting in no enzyme expression.  
The first step in the design of this sequence was to choose a PAM (protospacer adjacent 
motif) site in fdc1 gene (see Annex G). PAM is a DNA sequence recognized by Cas9 directly 
downstream of the target sequence and is composed of two guanines (5’-NGG-3’). In this case, 
PAM was selected between bases 109 and 111 of the fdc1 gene. After this it was necessary to 
identify the protospacer (guide sequence), that is the part of the sgRNA sequence that is 
complementary to the target sequence. This sequence possesses the first three bases of the 
PAM site and the previous 17 bp in fdc1 gene. Following, the homology zones, correspondent 
to the 50 bp upstream and downstream of the 8 bp deletion. 
Next, to design the DNA fragment for CRISPR-Cas9 (gBlock) the identified sequences 
were organized in the following order: 50 bp upstream homology, 50 bp downstream 
homology and guide sequence (Figure 5). The BsaI recognition site was also inserted in both 
ends of the gBlock. 
 
 
 
Figure 5: Synthetized gBlock: Yellow: BsaI recognition site; White: pCRCT complementarity; Light blue: 50 bp upstream 
homology zone; Gray: 50 bp downstream homology zone; Green: guide sequence. 
 
This enzyme does not cut the DNA at the recognition site and to ensure that the 
digested gBlock ligates with the plasmid, the same adjacent bases to the BsaI sites in the 
plasmid were added in the gBlock. This also ensures the insertion of the gBlock with the right 
GGTCTCCCCAAAGATGAAGATGACTTAATCGAAATTACCGAAGAGATTGATCCAAAT
CTCGACAATTATGAGGAAGGCCTATGAATCCCACTTACCAGCCCCGTTATTTAAAATT
GATCCAAATCTCGAAGTTAGAGCGAGACC 
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orientation. It was important to include the PAM sequence in the 8 bp deletion (see Annex G) 
to prevent continuous recognition and cleavage by CRISPR-Cas9 after the recombination 
event. A scheme showing fdc1 gene after CRISPR-Cas9 method is present in Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.8.2 Golden Gate Assembly and CRISPR-Cas9 method 
 
To knockout the fdc1 gene from S. cerevisiae CEN.PK2-1C CRISPR-Cas9 technology was 
used. For this purpose, the synthetized gBlock was inserted into pCRCT vector using Golden 
Gate Assembly technique (Engler et al., 2008). First, a ligation mix of 10 µL was prepared 
containing 2.5 µL BsaI (Thermo), 0.45 µL T4 ligase (Thermo), 1 µL T4 ligase buffer, 50 ng of 
plasmid and the 50 ng gBlock. The mix was maintained at 37oC during 30 min followed by 5 
min at 50oC and then 5 min at 80oC. The incubation at 50oC was performed to re-digest any 
plasmid that might still contain a BsaI restriction site, while the 80oC incubation aimed the 
inactivation of both restriction enzyme and ligase. Next, the ligation mix was transformed into 
E. coli NZY5α cells and the transformants plated in LB supplemented with X-GAL (20 μg/ml) 
and ampicillin. The insertion was confirmed by blue and white screening, colony PCR (see PCR 
conditions in Table E3 in Annex E) of white colonies and sequencing. After that, the vector 
was extracted from an overnight grown culture using the extraction kit and transformed in S. 
Figure 6: Scheme showing fdc1 after Cas9 cleavage and homologous recombination. 
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cerevisiae CEN.PK2-1C strain using the method described in section 3.5. The recombination 
events take place right after transformation since the CRISPR-Cas9 machinery is regulated by 
constitutive promoters not requiring any kind of induction.  
 
3.8.3 Plasmid curing 
 
To introduce the plasmids carrying the curcumin pathway in the knockout strain it was 
first necessary to remove the pCRCT plasmid. For this purpose, a positive colony (Δfdc1) was 
grown in YPD overnight (to induce plasmid loss) and then plated in YNB supplemented with 
uracil and 5-FOA. When 5-FOA is added to the medium, the enzyme produced by the URA3 
gene, codified by pCRCT, converts 5-FOA into a toxic compound, acting as a negative marker. 
Afterwards, the colonies were re-plated in the same media two more times, to ensure the 
plasmid loss, and finally plated in YNB +URA solid media and stored. After that, S. cerevisiae 
CEN.PK2-1C Δfdc1 strain was transformed and tested for curcumin production. 
3.8.4 Knockout confirmation 
 
In order to confirm fdc1 knockout by CRISPR-Cas9 method, a colony PCR was performed 
on a plasmid cured colony (see PCR conditions in Table E3 in Annex E) using specific primers 
to the fdc1 gene (FDC FW and FDC REV) (Table D2-Annex D) and Phusion High Fidelity DNA 
polymerase. This primer pair was designed to amplify the first 761 bp of the fdc1 gene in yeast 
genome. The resulting fragment were purified from the agarose gel using the purification kit 
and sequenced with the same pair of primers. The sequencing results allowed to confirm the 
knockout of the fdc1 gene.
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4  RESULTS AND DISCUSSION  
 Evaluation of ferulic acid toxicity and conversion 
 
Ferulic acid, like other plant phenolic compounds, is a natural antioxidant and can act as 
potent inhibitor against fermentative microorganisms (Borges et al., 2013). Therefore, the 
effect of ferulic acid in yeast growth needs to be evaluated. To produce curcumin in an 
engineered yeast using ferulic acid as substrate, it is first important to verify the concentration 
at which that compound is not toxic to the cell. It is also important to ensure that the defined 
ferulic acid concentration does not delay the cell growth which could reduce the efficiency of 
the process.  
 Adeboye et al. (2014) studied the inhibitory effect of ferulic acid and other phenolic 
compounds in an industrial strain of S. cerevisiae. The authors concluded that ferulic acid was 
too toxic at a concentration of 1.8 mM or higher. However, in a different study the same 
authors did not observe an inhibitory effect using the same concentration (1.8 mM) but at 
larger scale in a bioreactor (Adeboye et al., 2015). The researchers attributed the changes in 
the toxicity to the scaling up. Besides, as far as it is known, there are no other works in which 
ferulic acid toxicity was studied in yeast and since curcumin has never been produced in yeast 
there is no information about the proper ferulic acid concentrations to be used.  
For this purpose, S. cerevisiae CEN.PK2-1C wild type strain was grown with different 
concentrations of ferulic acid. The fermentation was maintained during 48 h and the cell 
growth profile for each ferulic acid concentration can be observed in Figure 7. 
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Figure 7: Growth curves of S. cerevisiae CEN.PK2-1C strain in YNB media supplemented with different concentrations of ferulic 
acid (0.5 mM; 1 mM; 2 mM and 5 mM). The fermentation was carried out during 48 h. 
 
 
The addition of ferulic acid coincided with almost the middle of exponential phase. For 
the assay in which 5 mM of ferulic acid were added, growth inhibition is notorious right after 
addition, revealing that at this concentration ferulic acid is toxic to the yeast. The inhibition is 
not observed in the remaining tests since the growth curves profile resemble the control. 
Between the 2 h and the 12 h (exponential growth phase) the specific growth rate of the 
control was 0.32 h-1. This growth rate was similar to the rates obtained for the remaining 
assays: 0.5 mM (0.32 h-1), 1 mM (0.31 h-1) and 2 mM (0.30 h-1). Between the addition of ferulic 
and the 12 h, the specific growth rates for 0.5 mM and 1 mM (0.13 h-1 and 0.12 h-1) resemble 
the control (0.12 h-1). However, the growth rate calculated for the 2 mM assay is lower than 
the one of the control (0.09 h-1). This may indicate that the addition of 2 mM of ferulic to the 
culture medium in some way delayed the growth of the culture. Nevertheless, after 48 h of 
fermentation the biomass produced in the 2 mM assay was similar to the biomass produced 
in the control assay. Based on these results, and taking into account a 120 h fermentation for 
curcumin production (ensuring the coverage of the whole fermentation process), a 
concentration of 2 mM of ferulic acid was selected to produce curcumin in the engineered S. 
cerevisiae strains in a first phase. 
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During the fermentation process samples were also taken for HPLC analysis. The goal of 
the sampling was to evaluate whether in fact the ferulic acid is converted to 2-Methoxy-4-
vinylphenol by S. cerevisiae. The enzyme that may be responsible for the conversion is the 
FDC enzyme. The concentrations of ferulic acid during the fermentation and 2-Methoxy-4-
vinylphenol at the end of the fermentation are presented in Table 8. 
 
Table 8: Ferulic acid and 2-Methoxy-4-vinylphenol concentrations obtained during fermentation of S. cerevisiae CEN.PK2-1C 
in YNB media supplemented with different concentrations of ferulic acid. 2-Methoxy-4-vinylphenol was quantified at the end 
of the fermentation.   
Assay  [Ferulic acid] mM [2-Methoxy-4-
vinylphenol] mM 6 h 24 h 48 h 
Control 0 0 0 0 
0.5 mM 0.451 0.439 0.409 0.016 
1 mM 0.798 0.727 0.659 0.058 
2 mM 1.674 1.613 1.538 0.099 
 
 
In the experiments conducted with 0.5 mM, 1 mM and 2 mM of ferulic acid, these 
concentrations decrease over time and vestigial concentrations of 2-methoxy-4-vinylphenol 
were quantified in the end of the fermentation. In addition, 2-methoxy-4-vinylphenol 
concentrations increased with the ferulic concentration added to the media, as expected. 
Hereupon, the appearance of 2-methoxy-4-vinylphenol as well as the consumption of ferulic 
acid confirmed the activity of the endogenous FDC in S. cerevisiae CEN.PK2-1C. No 2-methoxy-
4-vinylphenol was observed in the control. The concentrations of 2-methoxy-4-vinylphenol 
are lower when compared with ferulic the acid consumption because 2-methoxy-4-
vinylphenol is converted in simpler compounds by yeast.    
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 Pathways construction  
 
In order to produce curcumin in an engineered S. cerevisiae, 3 biosynthetic pathways 
were constructed. The first two, both carrying the CUS gene from O. sativa together with 4CL’s 
from different organisms. The first with 4CL isoform 1 from A. thaliana and the other with 4CL 
from L. erythrorhizon. The third pathway was composed by 4CL1 from A. thaliana and DCS and 
CURS from C. longa codon optimized for yeast. The pathways construction was carried out 
using traditional molecular biology techniques, PCR or molecular cloning. 
 
4.2.1 CUS pathways  
 
As mentioned before, pSP-GM1 possesses two multiple cloning sites. To construct pSP-
GM1_At4CL_CUS and pSP-GM1_Le4CL_CUS, 4CL genes were cloned under control of TEF1 
promoter and the respective terminator and CUS under control of PGK1 promoter, the 4CL 
genes were cloned first because the NotI restriction enzyme used to insert Le4CL and At4CL 
cuts the CUS gene. In Figure 8 it is possible to observe the results of colony PCR used to confirm 
Le4CL insertion in pSP-GM1 plasmid. 
 
 
 
The colony PCR served to prove which colonies that grew in LB selective medium 
possessed the plasmid pSP-GM1_Le4CL. For this purpose, an amplification of 2412 bp 
Figure 8: Colony PCR agarose gel 0.7 % to confirm the insertion of L. erythrorhizon 4CL in pSP-GM1 using TEF1p_REV and 
ADH1t_FW primers. M: represents the DNA ladder; 1 to 12: represents the tested colonies; Expected positive band size is 
2412 bp.  
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(positive), Le4CL plus the amplified promoter and terminator regions, is expected. The use of 
two distinct restriction enzymes prevents the vector re-ligation and an amplification of 551 bp 
(negative) refers that these cells have been transformed with undigested vector. For pSP-
GM1_Le4CL, lanes 1, 2, 3, 5, 7, 8, 10 and 12 represent positive colonies and 4 and 9 are 
negatives. For pSP-GM1_At4CL (data not shown) positive colonies amplification had 2161 bp. 
Next, positive colonies were picked arbitrarily and grown overnight in selective media. Then, 
the plasmid DNA was extracted and digested with one and two of the enzymes used to insert 
the genes in the vector. The digestion was run in agarose gel to confirm the result obtained 
by colony PCR. In Figure 9 is shown, as an example, the digestion of pSP-GM1_ At4CL with 
NotI and PacI.  
 
 
 
Figure 9: Digestion of pSP-GM1_At4CL to confirm the insertion of A. thaliana 4CL1 in pSP-GM1. Lanes 1 and 2 represent a the 
digestion of the picked positive colony; M represents the DNA ladder (NZYladder III, NZYTech). The plasmid was extracted 
and digested with NotI (lane 1) and with NotI and PacI (lane 2) Band sizes expected: 1- 9049 bp; 2- 7404 bp and 1718 bp.  
 
In the lane 1, the plasmid was digested with NotI and in the lane 2 with NotI and PacI. 
In the well 1, a ≈10000 bp was obtained which matches the linearized pSP-GM1_At4CL size 
(9049 bp). In well 2 two bands are visible, one with about 7500 bp and another with ≈2000 bp 
which matches the size of the insertion (1718 bp). The same process was used for pSP-
GM1_Le4CL and then positive plasmids were sequenced and no errors were detected in the 
genes sequence. 
After the construction of pSP-GM1_Le4CL and pSP-GM1_At4CL, the CUS gene was 
inserted to complete the curcumin biosynthetic pathways. In Figure 10 is displayed the colony 
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PCR agarose gel for pSP-GM1_Le4CL_CUS. In this case, the positive amplification possesses 
1712 bp and the negative 491 bp.  
 
 
 
 
Lanes 4, 6, 7, 8, 9, 10, 11 clearly exhibit a band with the expected positive size, however 
the lanes 4, 8, 9, 10 and 11 exhibit also an unspecific amplification, perhaps in E. coli genome. 
Since colonies from lane 6 and 7 do not have unspecific amplification they were selected for 
the following steps. Supposedly positive pSP-GM1_Le4CL_CUS and pSP-GM1_At4CL_CUS 
colonies were grown overnight and the plasmids extracted. The plasmids were then digested. 
The digestion of pSP-GM1_At4CL_CUS is shown as an example in Figure 11.  
 
Figure 10: Colony PCR agarose gel 0.7 % to confirm the insertion of O. sativa CUS in pSP-GM1_Le4CL using PGK1p_FW and 
CYCt_REV primers. M: represents the DNA ladder (NZYladder III, NZYTech); 1 to 12: represents the tested colonies. Expected 
positive band size is 1712 bp   
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The digestion also confirmed the insertion of the CUS. In the well 1 the plasmid was 
digested with BamHI being obtained a band > 10000 bp corresponding to the linearized 
plasmid. For the digestion with BamHI and HindIII (well 2) two bands were obtained, first a 
≈1400 bp corresponding to CUS (1214 bp) and the other matching the pSP-GM1_At4CL size 
(9049 bp). The same results were obtained for the digestion of pSP-GM1_Le4CL_CUS. The 
construction was also confirmed by sequencing the CUS gene. Hereupon, plasmids pSP-
GM1_Le4CL_CUS and pSP-GM1_At4CL_CUS (Figure 12) were transformed into S. cerevisiae 
CEN.PK2-1C strain. 
 
 
 
 
 
 
 
 
 
Figure 11: Digestion of pSP-GM1_At4CL_CUS to confirm the insertion of O. sativa CUS in pSP-GM1_At4CL. The plasmid of a 
positive colony was extracted and digested with BamHI and HindIII. Lane 1 represent the digestion with BamHI and the expect 
band size is 10193 bp. Lane 2 represent the digestion with BamHI and HindIII and the expected band sizes are 9049 bp and 
1214 bp; M represents the DNA ladder (NZYladder III, NZYTech).  
 
Figure 12: Plasmids pSP-GM1_At4CL_CUS and pSP-GM1_Le4CL_CUS  
 
4. Results and Discussion 
46 
4.2.2 DCS and CURS pathway  
 
To construct pSP-GM1_DCS_4CL_CURS, DCS was cloned under control of TEF1 promoter 
and 4CL gene was put under control of PGK1 promoter. To express the CURS gene, TDH3 
promoter and synthetic terminator 27 were also inserted in the plasmid to create a third 
regulatory region (see strategy in section 3.3).  
The first step in the construction of this pathway was to amplify DCS, At4CL, the 
promoter TDH3 and CURS1 gene.  In this pathway, At4CL was inserted in a different multiple 
cloning site. The synthetic terminator 27 sequence was present in the primer used to amplify 
CURS1. The codon optimized DCS gene was first inserted in pSP-GM1 plasmid. Positive 
colonies were selected by colony PCR (Figure 13, A). Afterwards, two positive colonies were 
grown overnight and the extracted plasmid was digested to confirm the insertion of DCS in 
pSP-GM1 (Figure 13, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: A: Colony PCR agarose gel 0.7 % to confirm the insertion of codon-optimized DCS in pSP-GM1 using TEF1p_REV 
and ADH1t_FW primers. M: represents the DNA ladder (NZYladder III, NZYTech); 1 to 11: represents the tested colonies. 
Expected positive band size is 1626 bp; B: Digestion of pSP-GM1_DCS to confirm the insertion of codon optimized DCS in pSP-
GM1. The plasmids of two positive colonies were extracted and digested with NotI and SacI. Lane 1 and 3 represent the 
digestion with NotI and the expect band size is 8539 bp. Lane 2 represent the digestion with NotI and SacI and the expected 
band sizes are: 7404 bp and 1135 bp; M represents the DNA ladder (NZYladder III, NZYTech). 
 
[A] 
[B] 
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For this case, positive amplifications possessed 1626 bp and were obtained in all lanes 
except in lanes 3 and 7. The digestion confirmed the insertion of DCS in the two colonies 
picked, as can be visualized in the double digestion (lanes 2 and 4), as well as in linearization 
(lanes 1 and 3). 
After sequencing, At4CL was inserted in plasmid pSP-GM1_DCS. The same process, 
colony PCR and digestion, was used to confirm the insertion. The positive amplification (2196 
bp) was observed in Figure 14 (A) in the lane 5 while in the other lanes negative amplifications 
(499 bp) were observed. The digestion also confirmed the insertion of At4CL in pSP-GM1_DCS 
(Figure 14, B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A: Colony PCR agarose gel 0.7 % to confirm the insertion of A. thaliana 4CL1 in pSP-GM1_DCS using PGK1p_FW 
and CYCt_REV primers. M: represents the DNA ladder (NZYLadder III, NZYTech); 1 to 12: represents the tested colonies. 
Expected positive band size is 2196 bp; B: Digestion of pSP-GM1_DCS_4CL to confirm the insertion of 4CL in pSP-GM1_DCS. 
The plasmid of the positive colony was extracted and digested with BamHI and XhoI. Lane 1 represent the digestion with 
BamHI and the expect band size is 10167 bp. Lane 2 represent the digestion with BamHI and XhoI and the expected band 
sizes are: 8539 bp and 1628 bp; M represents the DNA ladder (NZYLadder III, NZYTech). 
[A] 
[B] 
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After confirming by sequencing that no errors were present, the TDH3 promoter was 
cloned in the plasmid. The colony PCR results can be observed in Figure 15 (A) and the 
digestion in Figure 15 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Again, besides the positive amplification, in some lanes are visualized some unspecific 
amplification. The plasmid from colony 10 was selected for the next steps. The digestion and 
sequencing confirmed the insertion of TDH3 promoter making pSP-GM1_DCS_CURS_TDH3 
plasmid. Afterwards, pSP-GM1_DCS_CURS_TDH3 and the amplicon composed by codon 
optimized CURS and the synthetic terminator 27 were also inserted. The results of the colony 
PCR and of the digestion of the positive colony is shown in Figure 16. 
 
  
 
Figure 15: A: Colony PCR agarose gel 0.7 % to confirm the insertion of TDH3 promoter in pSP-GM1_DCS_4CL using pSP-GM1 
FW and pSP-GM1-REV primers. M: represents the DNA ladder (NZYLadder III (NZYTech)); 1 to 12: represents the tested 
colonies. Expected positive band size is 1505 bp; B: Digestion of pSP-GM1_DCS_4CL_TDH3 to confirm the insertion of TDH3 
promoter in pSP-GM1_DCS_4CL. The plasmid of a positive colony was extracted and digested with AscI and AvriI. Lane 1 
represent the digestion with AscI and the expect band size is 11175 bp. Lane 2 represent the digestion with AscI and AvrII 
and the expected band sizes are: 10167 bp and 1008 bp; M represents the DNA ladder (NZYLadder III (NZYTech)). 
 
[A] 
[B] 
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Positive bands (1984 bp) were obtained in two lanes and a negative one (685 bp) in lane 
1. The digestion of colony 3 plasmid confirmed the insertion of CURS1 with the synthetic 
terminator. Finally, the plasmid pSP-GM1_DCS_4CL_CURS1 (Figure 17) was sequenced and 
transformed into S. cerevisiae CEN.PK2-1C strain.  
 
 
 
 
 
 
 
 
 
Figure 16 : A: Colony PCR agarose gel 0.7 % to confirm the insertion of codon optimized CURS1 with synthetic terminator in 
pSP-GM1_DCS_4CL_THD3 using using TDH3_middle FW and pSP-GM1 REV primers. M: represents the DNA ladder 
(NZYLadder III, NZYTech); 1 to 4: represents the tested colonies. Expected positive band size is 1984 bp; B: Digestion of pSP-
GM1_DCS_4CL_CURS1 to confirm the insertion of CURS1 with synthetic terminator_27 in pSP-GM1_DCS_4CL_THD3. The 
plasmid of a positive colony was extracted and digested with AscI and SphI. Lane 1 represents the digestion with AscI and the 
expect band size is 12413 bp. Lane 2 represents the digestion with AscI and SphI and the expected band sizes are: 11175 bp 
and 1238 bp; M represents the DNA ladder (NZYLadder III, NZYTech). 
 
 
Figure 17: Plasmid pSP-GM1_DCS_4CL_CURS1. 
[A] [B] 
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 Batch fermentation – Curcumin production 
 
The production of curcumin in heterologous organisms has the advantage of conferring 
colour to the culture media due to the bright yellow colour of curcumin, which comprises an 
expedite way to qualitatively confirm the production of the target compound.  S. cerevisiae 
does not hold a specific polyphenol transporter, thus it was expected that the produced 
curcumin remains inside the cells being the biomass responsible for the yellow colour of the 
culture. At the end of the fermentation, the yellow cultures were collected and curcumin was 
extracted using methanol.  
 
4.3.1 Assays with 2 mM ferulic acid 
 
In a first phase, S. cerevisiae CEN.PK2-1C cultures carrying the plasmids pSP-
GM1_At4CL_CUS, pSP-GM1_Le4CL_CUS and pSP-GM1_DCS_4CL_CUR1S were cultivated in 
YNB -URA selective media and 2 mM of ferulic acid were added to culture when an OD600nm> 
0.2 was reached. The growth was followed until a continuous OD600nm was obtained. The 
growth curves of S. cerevisiae CEN.PK2-1C carrying the curcumin biosynthetic pathways and a 
control (S. cerevisiae CEN.PK2-1C wild strain) are shown in the Figure 18. 
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Figure 18: Growth curves of S. cerevisiae CEN.PK2-1C strain (control) and S. cerevisiae CEN.PK2-1C carrying the curcumin 
biosynthetic pathways in YNB -URA media (except for the control: YNB +URA) supplemented with 2 mM of ferulic acid.  
 
The specific growth rates calculated for the exponential phases were: 0.093 h-1 (Control), 
0.085 h-1 (At4CL_CUS), 0.090 h-1 (Le4CL_CUS) and 0.089 h-1 (DCS_4CL_CURS1). The growth 
specific rates of the engineered strains, as well as the maximum growth obtained were very 
similar to the control revealing that the plasmids did not delay the cell growth. However, 
regarding curcumin production, no yellow colour formation could be observed in the culture 
media after 120 h of fermentation. Hereupon, the concentration of ferulic acid and the 
formation of 2-Methoxy-4-vinylphenol in the end of the fermentation were evaluated. The 
results obtained are shown in Table 9.  
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Table 9:  Ferulic acid and 2-Methoxy-4-vinylphenol concentrations obtained by HPLC after fermentation of S. cerevisiae 
CEN.PK2-1C strain (control) and S. cerevisiae CEN.PK2-1C carrying the curcumin biosynthetic pathways in YNB media 
supplemented with 2 mM of ferulic acid. 
 [Ferulic acid] (mM) [2-Methoxy-4-vinylphenol] (mM) 
Control 1.667 0.12 
At4CL_CUS 1.465 0.04 
Le4CL_CUS 1.521 0.02 
DCS_4CL_CURS 1.709 0.04 
 
 
The concentration of ferulic acid obtained for the control was analogous to that 
obtained in the experiments with engineered strains. This showed that ferulic acid may have 
only been converted to 2-Methoxy-4-vinylphenol and 2-Methoxy-4-vinylphenol degradation 
products, thus not being used to produce curcumin. The fermentations were repeated and no 
curcumin was visually observed. 
Typically, in fermentations performed with rich media the cell concentrations and 
protein expression levels are higher than in fermentations with minimal media. This fact may 
favour the production of heterologous compounds in engineered yeasts. Jordan and Nash 
(2015) studied the rate of episomal plasmid loss in yeast in the absence of selective pressure. 
The authors concluded that yeast retain the plasmids much longer than expected suggesting 
that growth in non-selective medium may be a viable process. Thus, it was decided to use rich 
medium to test curcumin productivity in order to identify whether higher concentrations of 
biomass could result in the production of curcumin. The engineered strains were inoculated 
into YPD (without selective pressure) and the ferulic acid was added when an OD600nm > 2 was 
reached. The OD600nm was followed during the fermentative process resulting in the growth 
curves presented in Figure 19. 
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As expected, the production of biomass in rich media (Control: 6.24 g/L) was higher 
than in minimal media (Control: 1.39 g/L). However, after 120 h of fermentation and removal 
of the culture media (due to the yellowish colour of YPD) no yellow colour of biomass was 
observed which was also confirmed by the concentrations of ferulic and 2-Methoxy-4-
vinylphenol at the end of the fermentation (Table 10).  
 
Table 10: Ferulic acid and 2-Methoxy-4-vinylphenol concentrations obtained by HPLC after fermentation of S. cerevisiae 
CEN.PK2-1C strain (control) and S. cerevisiae CEN.PK2-1C carrying the curcumin biosynthetic pathways in YPD media 
supplemented with 2 mM of ferulic acid.  
 
 
 
 
 
 [Ferulic acid] (mM) [Vinylphenol] (mM) 
Control 1.570 0.02 
At4CL_CUS 1.441 0.01 
Le4CL_CUS 1.680 0.08 
DCS_4CL_CURS 1.601 0.02 
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Figure 19: Growth curves of S. cerevisiae CEN.PK2-1C strain (control) and S. cerevisiae CEN.PK2-1C carrying the curcumin 
biosynthetic pathways in YPD media supplemented with 2 mM of ferulic acid. The fermentation was followed during 68 h.  
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4.3.2 Decreasing ferulic acid concentration   
 
Ferulic acid is a phenolic compound present in lignocellulosic biomass and is known to 
be toxic to cell growth and fermentative capability. Shin et al. (2011) determined the optimal 
substrate concentration for resveratrol production in yeast. For that purpose, the substrate, 
p-coumaric acid was added to the media in a concentration range of 8 to 80 mg/L. Using a 
concentration of 16 mg/L, the authors achieved the highest yield of resveratrol and superior 
concentrations of substrate reduced the produced resveratrol concentrations. The 
researchers did not identify a reason for such results but suggested that phenolic acids like 
coumaric or ferulic, may interrupt the central metabolism in yeast.  
Hereupon, it was decided to test if with a ferulic acid concentration of 16 mg/L (0.08 
mM), 25-fold lower than the one used in previous tests, the production of curcumin would be 
achieved. With that purpose, the recombinant strains were inoculated in YNB -URA selective 
media and 16 mg/L of ferulic acid were added in the beginning of the fermentation process. 
The yellow colour formation was visualized in the fermentation with S. cerevisiae CEN.PK2-1C 
harbouring the Le4CL_CUS pathway confirming the curcumin production (Figure 20). The 
curcumin present in the cells was extracted with methanol and analysed in HPLC (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Yellow colour formation in the culture media. A: Control: S. cerevisiae CEN.PK2-1C; B: S. cerevisiae CEN.PK2-1C 
harbouring Le4CL_CUS pathway. 
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The assays were performed in duplicate and concentrations of 87.3 ng/L and 39.7 ng/L 
were detected corresponding to a yield of 0.55 % and 0.25 %, respectively. The difference in 
curcumin productivity between the duplicates harbouring Le4CL_CUS pathway may be 
explained by the different plasmid copy number of the cultures, that is a common problem 
when episomal plasmids are used because the copy number of the plasmid will affect the level 
of recombinant protein production.  
Afterwards, the production was also tested in a different S. cerevisiae strain. For that 
purpose, pSP-GM1_Le4CL_CUS plasmid was transformed into S. cerevisiae Y02321 strain. The 
fermentation was carried out in YNB -URA with 16 mg/L of ferulic acid. The obtained growth 
curve is displayed in Figure 22. 
A 
B 
Figure 21: HPLC analyses of curcumin produced by recombinant S. cerevisiae CEN.PK2-1C carrying Le4CL_CUS pathway. 
Chromatogram A represents the authentic standard of curcumin and chromatogram B represents the sample that contains 
curcumin produced by recombinant S. cerevisiae. Note: The other peaks visualized in A is due to the 95 % purity of the 
curcumin standard. 
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The production of curcumin was also visually observed when S. cerevisiae Y02321 
strain was used as a host. The HPLC analysis confirmed a concentration of 51 ng/L which 
represents a yield of 0.32 %. Comparing the growth curves of S. cerevisiae Y02321 strain with 
CEN.PK2-1C strain in YNB -URA, this strain produced a higher amount of biomass which is a 
desirable feature for metabolite production.  
After attempts of reproducing the results in both strains using colonies from the streak 
plate, a yellow colour formation was no longer observed in the culture media. The 
fermentations were repeated under the same and with different conditions to eliminate the 
possibility of human error. All the culture media components were prepared fresh and 
different temperatures (28oC, 32oC, 35oC and 37oC) and different substrate concentrations (80 
mg/L and 160 mg/L) were tested.    
A reasonable explanation for this lack of reproducibility could be the plasmid copy 
number loss over generations. Futcher and Cox (1983, 1984) studied the maintenance and 
copy number of 2µm based plasmids in yeast populations and concluded that daughter cells 
might receive less than half of the plasmids from parent cells because yeast division is not 
symmetrical. The formation of cells with low copy number per cell may increase over 
generations. The use of colonies with high generation level may result in cultures without 
sufficient gene expression for curcumin production.  
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Figure 22: Growth curves of S. cerevisiae Y02321 strain (control) and S. cerevisiae Y02321 carrying the curcumin biosynthetic 
pathway Le4CL_CUS in YNB -URA (Control: YNB +URA) media supplemented with 16 mg/L (0.08 mM) of ferulic acid. The 
fermentation was carried out during 120 h. 
Production of curcumin by an engineered Saccharomyces cerevisiae 
57 
 To prevent plasmid copy loss over generations, S. cerevisiae CEN.PK2-1C strain was 
again transformed with Le4CL_CUS pathway. After transformation, three colonies grown in 
the transformation plate were randomly selected and tested for curcumin productivity 
ensuring a minimal generational level. After fermentation, although cultures did not present 
a yellow colour, the methanol extraction was performed and the extract analysed by HPLC. 
The curcumin content quantified in each culture is displayed in Table 11.  
 
 
Table 11: Curcumin produced by three different yeast cultures of S. cerevisiae CEN.PK2-1C carrying Le4CL_CUS pathway 
obtained from three colonies of the transformation plate. YNB -URA culture media was used and a concentration of 16 mg/L 
of ferulic was used as initial substrate concentration. 
 
Yeast culture Curcumin produced (ng/L) 
CEN 1 4.41 
CEN 2 0 
CEN 3 7.57 
 
 
Curcumin was in fact produced in two of three yeast cultures, although at lower yields 
than the ones previously obtained when yellow colour was visualized. However, the fact that 
curcumin was detected by HPLC corroborates the successful biosynthetic pathway 
engineering in S. cerevisiae. Hereupon, a more extensive test was performed. The plasmid 
carrying Le4CL_CUS pathway was once again transformed into S. cerevisiae strains CEN.PK2-
1C and Y02321 and six colonies of each strain were picked and curcumin productivity was 
tested using the previously conditions. The obtained results are shown in Table 12. 
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Table 12: Curcumin production by three different yeast cultures of S. cerevisiae CEN.PK2-1C and of S. cerevisiae Y02321 
carrying Le4CL_CUS pathway obtained from six colonies of the transformation plate. YNB -URA culture media was used and 
a concentration of 16 mg/L of ferulic was used as initial substrate concentration. CEN1 to 6 refer to cultures using recombinant 
S. cerevisiae CEN.PK2-1C strain and Y1 to 6 refer to cultures using recombinant S. cerevisiae Y02321 strain.  
Yeast culture Curcumin produced (ng/L) Yield (%) 
CEN1 4.01 0.03 
CEN2 3.02 0.02 
CEN3 to CEN6 0 - 
Y1 0 - 
Y2 16.7 0.11 
Y3 55.5 0.35 
Y4 5.33 0.03 
Y5 4.13 0.03 
Y6 9.09 0.12 
 
 
 Yellow colour formation was only observed in cultures Y2, Y3 and Y6 although 
curcumin was detected in a set of other samples however in low concentrations when 
compared with yellow cultures.  Regarding the S. cerevisiae CEN.PK2-1C strain, the production 
of curcumin was only confirmed in two of the six colonies tested. On the other hand, with the 
strain YO2321 the production was observed in five of the six tested colonies. This result may 
indicate that strain Y02321 is the best producer. In fact, the use of colonies with low 
generation number enables the production of curcumin. The yeast culture 3 from YO2321 
strain was the best producer achieving curcumin levels (55.5 ng/L and yield of 0.35 %) alike to 
those previously obtained.  
This is the first report on the construction of a pathway to produce curcumin in S. 
cerevisiae. However, the production of curcumin visually detectable was only achieved in one 
of the three pathways constructed: 4CL from L. erythrorhizon and CUS from O. sativa. 
Nevertheless, curcumin was also detected in not yellow cultures. The fact that the yellow 
colour formation was not observed in At4CL_CUS and DCS_4CL_CURS cultures may indicate 
that curcumin is being produced but in very low concentrations. In the future, more tests with 
these pathways are required to confirm if in fact curcumin is being or not produced.   
Although curcumin was produced using a pathway harbouring Le4CL and CUS the 
yields obtained were very low when compared with those obtained in E. coli. One possible 
explanation is the low amount of malonyl-CoA available to produce heterologous compounds 
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like curcumin. To synthesize one molecule of curcumin, two molecules of malonyl-CoA are 
required. In S. cerevisiae, malonyl-CoA concentration is maintained at low levels due to the 
intrinsic tight regulation of the fatty acid biosynthesis (Chen et al., 2017). The remaining 
malonyl-CoA may not be sufficient to produce high amounts of curcumin. The culture media 
used, YNB, in due to limit high biomass production. Other factors such as ferulic acid 
bioavailability or the extraction method, that will be discussed in 4.5, may also contributed to 
the low yields. 
 FDC knockout 
 
The fdc1 gene codifies for ferulic acid decarboxylase (FDC) in S. cerevisiae. This enzyme 
catalyses the decarboxylation of ferulic acid producing the corresponding vinyl derivate as a 
detoxification process. The development of a fdc1 knockout strain may improve the curcumin 
productivity since the substrate consumption is prevented. CRISPR-Cas9 technology was used 
to cause an 8 bp deletion in the fdc1 gene (see fdc1 sequence in Annex D)  
The synthetized gBlock was first inserted in pCRCT plasmid using Golden Gate Assembly 
technique. The insertion was confirmed by blue and with screening, colony PCR (Figure 23) 
and sequencing.  
 
 
 
Figure 23: Colony PCR agarose gel 0.7 % to confirm the insertion of gBlock in pCRCT using pCRCT_FW and pCRCT_REV primers. 
M: represents the DNA ladder (NZYLadder III (NZYTech)); 1 to 12: represents the tested colonies; Expected positive band size 
is 521 bp. 
 
Positive amplification (521 bp) was verified in more than half of the colonies tested. 
The sequencing results also confirmed the insertion of gBlock in pCRCT. S. cerevisiae CEN.PK2-
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1C was transformed with pCRCT_gblock and the homologous recombination occurred during 
the transformation process.  Afterwards, a colony was randomly chosen and a colony PCR was 
performed to amplify fdc1 gene in yeast genome. The resulting band was extracted and 
sequenced confirming the 8 bp deletion. The alignment of the fdc1 gene sequence and the 
sequencing result is shown in Figure 24. 
 
 
 
The alignment confirmed the 8 bp deletion, between bases 104 and 113 causing an 
alteration on the reading frame of the fdc1 gene and an early stop in the translation. This 
strain was named S. cerevisiae CEN.PK2-1C Δfdc1. The open reading frames (ORFs) of the fdc1 
gene after the deletion are displayed in Figure 25. As expected the 8 bp deletion, in frame 1 
(same ORF as the native gene), caused an alteration on the reading frame and right after the 
deletion a stop codon is found. ORF2 presents the longest ORF and the protein translated is 
equal with the original FDC, except in the first 39 amino acids (not present in ORF2). Bhuiya et 
al., (2015) studied the structure of FDC enzyme. The authors identified three domains in the 
first 39 amino acids associated with three secondary structures of domain 1. The missing of 
these 39 amino acids may affect the whole enzyme structure and consequently its activity. 
However, as defined by Waterman et al. (1987), the nucleotide sequence composed by 6 A’s, 
ribosome binding site, is essential in the transduction initiation. This poly(A) is not present 
before the starting codon in ORF2, preventing the translation of this ORF, at least with high 
efficiency.  
Figure 24: Alignment of the fdc1 gene sequence against the sequencing results obtained by colony PCR of the fdc1 
gene after pCRCT_gblock curing.   
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Bhuiya et al. (2015) identified the FDC active site, composed by Glu285 and Arg175. 
The deletion of bases in one of these regions could be another suitable strategy to knockout 
fdc1 gene using CRISPR-Cas9 technology.  
The consumption of ferulic acid and the formation of 2-Methoxy-4-vinylphenol was 
studied using S. cerevisiae CEN.PK2-1C Δfdc1. YNB supplemented with the required amino 
acids and uracil was used for culture media and a concentration of 2 mM of ferulic acid was 
added. No 2-Methoxy-4-vinylphenol formation was quantified during the fermentation and 
the concentration of ferulic did not decrease (data not shown). This result confirmed the 
knockout of the fdc1 gene and consequently FDC inactivity.  
Afterwards, the pathway Le4CL_CUS was transformed into S. cerevisiae CEN.PK2-1C 
Δfdc1 strain and tested for curcumin productivity. Six colonies were tested and no curcumin 
production was detected by HPLC using this strain. More tests are required using the knockout 
strain, repeat the pathway transformation for instance, or even the plasmid curing process. 
Due to the low production yields and to the fact that ferulic acid is not completely transformed 
in 2-Methoxy-4-vinylphenol by the wild strain (Table 9) it is not expected that the knockout, 
by now, has a major influence on the production. 
 
 
 
Figure 25: 5’3’ Open Reading Frames after 8 bp deletion in fdc1 gene.  
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 Curcumin extraction  
 
The extraction method is a crucial step in the production of heterologous compounds 
because an inefficient extraction may compromise the whole process. When produced in E. 
coli, curcumin was extracted using ethyl acetate. However, in yeast this method did not work 
since the biomass remained yellow when in contact with this solvent suggesting that the 
curcumin remained inside the cells perhaps because of the lack of permeability of the yeast 
membrane to ethyl acetate. The extraction was tested using three other different methods: 
in the first two the cell lysis was performed using glass beads or ethanol 70 % followed by 
extraction with ethyl acetate and in the third only pure methanol was used. In the Table 13 is 
presented the curcumin concentration obtained from the same culture (S. cerevisiae Y02321 
harbouring Le4CL_CUS pathway) using the three methods and the respective yield.    
 
Table 13: Curcumin extracted with three different methods from the same culture (S. cerevisiae Y02321 harbouring 
Le4CL_CUS pathway, YNB -URA media supplemented with 16 mg/L of ferulic acid). The respective production yields are also 
presented.  
 
Comparing the curcumin extracted in methods involving cell lysis (Glass beads and 
Ethanol 70%) with the no cell lysis method (Methanol), the differences are very significant. 
More than 2- fold curcumin was extracted with glass beads and more than 4-fold when 
ethanol lysis was performed, revealing the importance of cell disruption in curcumin 
extraction from yeast. Comparing the two methods with lysis, with ethanol 70 % almost 2-fold 
more curcumin was extracted than with glass beads. The cell lysis performed with ethanol 70 
% and extraction with ethyl acetate revealed to be the most effective method to extract 
curcumin from yeast. The use of this method in all tests performed could have improved yields 
obtained in section 4.3.  
 
Extraction method Curcumin (ng/L) Yield (%) 
Glass beads 124.88 0.78 
Ethanol 70 % 233.42 1.46 
Methanol 51.01 0.31 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 Conclusions 
 
The main goal of this work was to produce curcumin from ferulic acid in an engineered S. 
cerevisiae. This main objective was accomplished. A pathway composed by L. erythrorhizon 
4CL and O. sativa CUS produced curcumin in two different strains: S. cerevisiae CEN.PK2-1C 
and S. cerevisiae Y02321. The maximum curcumin production was 233.42 µg/L. Regarding this 
work some other conclusions can be stated: 
- Three curcumin biosynthetic pathways were successfully constructed and validated. 
However, two of them did not result in visible curcumin production. More studies will 
be needed to evaluate the production using these pathways. 
- The ferulic acid toxicity was also evaluated. This compound revealed to be toxic at a 5 
mM concentration. With a concentration of 2 mM the growth was only slightly 
delayed. In this assay, the consumption of ferulic acid and the formation of 2-methoxy-
4-vinylphenol by S. cerevisiae CEN.PK2-1C wild type was also confirmed.  
- High concentrations of ferulic acid did not contribute for curcumin production. 
Contrariwise, low concentrations of ferulic acid (0.08 mM) allowed the curcumin 
production; 
- Cultures with high generation level did not contribute for the reproducibility because 
with the increase of the generation level the number of cells with low copy plasmid 
number possibly also increases;   
- The efficiency of extraction methods was addressed revealing the importance of cell 
lysis in the curcumin extraction from yeast;  
- A strain with a knockout to the fdc1 gene was developed using CRISPR-Cas9 
technology. The mutant did not consume ferulic acid and did not produce 2-methoxy-
4-vinylphenol proving the FDC inactivity. This technique proved to be a simple, rapid 
and effective DNA editing tool;   
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- The mutant harbouring the Le4CL_CUS did not produce curcumin, however more tests 
are necessary because the mutation only prevents the consumption of ferulic acid by 
yeast.  
In summary, besides the low yields, the construction of an engineered S. cerevisiae strain 
capable of producing curcumin from ferulic acid was successfully accomplished, as well as the 
development of an fdc1 knockout strain. Overall, the results obtained in this work open a door 
for further work in a not yet developed field, the curcumin production in yeast. 
 
 Future perspectives  
 
This work represents the first report where heterologous production of curcumin was 
achieved in an engineered S. cerevisiae. Nevertheless, the titters obtained were low, especially 
when compared to those obtained in engineered E. coli. In addition, in two of the constructed 
pathways there was no visible production of curcumin. More tests are required using these 
pathways because curcumin may not be produced in sufficient amounts to confer yellow 
colour to the culture but still be produced. Hereupon, the future perspectives can be framed 
in the optimization process both at the genetic and operational levels. Some suggestions for 
further research are given below:  
At the genetic level:  
- More efficient enzymes may increase the production yields. Therefore, different 4CL 
enzymes/isoenzymes should be tested. In addition, 4CL’s and CUS gene sequence may 
be codon-optimized.   
- The malonyl-CoA availability should be improved by the expression of malonyl-CoA 
synthase from plants or acetyl-CoA carboxylase (ACC) genes from other organisms or 
even the overexpression of the native ACC. 
- The use of inducible promoters could also enhance the curcumin productivity, such as 
GAL1 or synthetic components like Tet promoter adapted from bacteria. This kind of 
systems has the advantage of controlling the enzyme expression levels and can be 
useful for probing the optimal expression level;  
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- Strategies involving plasmids with higher copy number could also improve the results. 
In addition, the utilization of integrative plasmids or even yeast artificial chromosomes 
could be tested since they provide a more stable expression platform.  
- The expression of transporters may contribute to reduce the curcumin accumulation 
inside the cells increasing its threshold limit allowing higher production yields.  
- Insert degradation tags, taken from native yeast proteins, in curcumin biosynthetic 
genes may increase the half-lives of the heterologous proteins which may give a boost 
in the enzymatic activity. Localization tags can also be inserted to localize enzymes to 
native organelles in yeast. Organelles are supplies of important cofactors and can 
sequester toxic compounds. In mitochondria, for instance, the pool of acetyl-CoA is 
higher than in cytoplasm which may be advantageous for the expression of ACC. 
- The use of fusion proteins could increase curcumin productivity because 
protein::protein interactions can increase the metabolic efficiency. For example, the 
construction of DCS::CURS fusion protein could be tested. 
At operational level:  
- Other S. cerevisiae strains, culture media, substrate concentrations and extraction 
methods may be considered.  
- After optimization, the next step is the scale-up where the fed-batch culture operation 
mode may be implemented. Low-cost substrates could also be considered to decrease 
the production costs and develop a more sustainable process. Agricultural wastes rich 
in ferulic acid like rice bran, maize bran, pineapple peels, orange peels, and 
pomegranate peels may be used as substrates or a biosynthetic pathway may be 
constructed to produce curcumin from simple substrates (e.g., glucose).  
- The development of a rapid method for curcumin quantification, such as 
spectrophotometry would be very useful to evaluate production;  
- In addition, the evaluation of curcumin localization in yeast, such as its intracellular 
location (e.g., using microscopy techniques).
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6 ANNEXES 
Annex A – Strains  
 
Table A14: Escherichia coli and Saccharomyces cerevisiae strains used in this work. Genotypic information and strain source 
are also displayed.   
 
 
 
 
 
 
 
 
Strain Genotype information Source 
Escherichia coli 
NZY5α  
 
fhuA2∆(argF-lacZ)U169; phoA; glnV44; Φ80 
∆(lacZ)M15; gyrA96; recA1; relA1; endA1; thi-1; hsdR17 
NZYTech, 
Portugal  
Saccharomyces 
cerevisiae 
CEN.PK2-1C 
 
MATa; his3D1; leu2-3_112; ura3-52; trp1-289; MAL2-
8c; SUC2 
 
(Entian and 
Kotter, 2007) 
(Euroscarf 
30000A) 
 
Saccharomyces 
cerevisiae Y02321 
 
BY4741; MATa; ura3Δ0; leu2Δ0; his3Δ1; met15Δ0; 
YIL162w::kanMX4 
 
 (Euroscarf 
Y02321) 
Saccharomyces 
cerevisiae ΔFDC 
MATa; his3D1; leu2-3_112; ura3-52; trp1-289; MAL2-
8c; SUC2; Δfdc1 
This study 
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Annex B – Plasmids 
 
 In this annex are shown all the plasmids used to construct the curcumin 
biosynthetic pathway as well as the plasmids used for CRISPR-Cas9 (gene knockout). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure B1: pSP-GM1 plasmid map with its main features. The restriction enzymes sites used are highlighted (red).  
 
Figure B2: pCRCT plasmid map with its main features. The BsaI restriction sites are highlighted (red).  
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Table B15: Plasmids used in this study. 
 
 
 
 
 
 
 
Plasmids Features Source 
pNZY29 AmpR, rop, ori NZYTech 
pNZY29_DCS 
pNZY29 carrying DCS codon optimized from C. 
longa 
NZYTech 
pNZY29_CURS1 
pNZY29 carrying CURS1 codon optimized from C. 
longa 
NZYTech 
pAt4CL 
 
Plasmid carrying 4CL1 from A. thaliana, AmpR, 
ori 
(Rodrigues et al., 2015) 
pLe4CL 
 
Plasmid carrying 4CL from L. erythrorhizon, 
AmpR, ori 
(Rodrigues, 2014) 
pCUS 
 
Plasmid vector carrying CUS from O. sativa, 
AmpR, ori 
(Rodrigues et al., 2015) 
pTDH3 
 
Plasmid carrying TDH3 promoter from S. 
cerevisiae, AmpR, ori 
(Rodrigues, 2014) 
pSP-GM1 AmpR, URA3, ori, 2µ ori (Chen et al., 2012) 
pSP-GM1_At4CL pSP-GM1 carrying 4CL from A. thaliana This study 
pSP-GM1_Le4CL pSP-GM1 carrying 4CL from L. erythrorhizon This study 
pSP-GM1_At4CL_CUS pSP-GM1_At4CL carrying CUS from O. sativa This study 
pSP-GM1_Le4CL_CUS pSP-GM1_Le4CL carrying CUS from O. sativa This study 
pSP-GM1_DCS 
pSP-GM1 carrying DCS codon optimized from C. 
longa 
This study 
pSP-GM1_DCS_At4CL pSP-GM1_DCS carrying 4CL from A. thaliana This study 
pSP-GM1_DCS_At4CL_TDH3 
pSP-GM1_DCS_At4CL carrying TDH3 promoter 
from S. cerevisiae 
This study 
pSP-GM1_DCS_At4CL_CURS1 
pSP-GM1_DCS_At4CL_TDH3 carrying CURS1 
codon optimized from C. longa 
This study 
pCRCT AmpR, URA3, lacZ, ori, 2µ ori, iCas9, tracRNA (Bao et al., 2015) 
pCRCT_gblock pCRCT carrying gblock This study 
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Annex C – Codon optimized genes   
 
The DNA sequences of codon optimized genes DCS and CURS1 are present in this annex. The 
genes were codon optimized for S. cerevisiae and synthetized by NZYTech.   
 
Curcumin synthase I (CURS1) (1170 bp; GC%: 45.50) 
ATGGCCAATCTACATGCGCTTAGAAGGGAACAAAGAGCTCAGGGTCCAGCAACAATTATGGCTATCGGTACTG
CTACTCCACCTAACTTATACGAACAGTCGACATTCCCGGACTTTTATTTTCGTGTTACAAACTCAGATGATAAGC
AAGAACTCAAAAAAAAGTTTAGAAGAATGTGCGAAAAGACAATGGTGAAGAAGCGTTACCTGCATCTAACAG
AGGAAATATTAAAGGAGCGTCCTAAATTATGTTCTTACAAAGAAGCCAGTTTCGACGATAGACAAGATATTGT
GGTTGAAGAAATTCCACGTTTGGCTAAGGAAGCTGCTGAAAAGGCAATTAAAGAATGGGGTCGGCCAAAATC
TGAAATTACACATCTTGTCTTCTGTTCAATAAGTGGTATTGACATGCCAGGTGCGGACTACAGGTTAGCCACTT
TGCTGGGCTTACCTCTTACAGTTAATCGTCTTATGATTTATAGTCAGGCCTGTCACATGGGTGCTGCTATGTTGC
GAATAGCAAAAGATTTGGCTGAGAACAACAGAGGCGCCCGCGTATTGGTTGTGGCGTGCGAAATCACAGTTC
TGTCTTTCAGAGGTCCAAACGAGGGAGATTTTGAAGCATTAGCTGGACAAGCGGGCTTTGGCGACGGGGCCG
GCGCGGTCGTTGTAGGTGCCGACCCGCTCGAAGGTATAGAAAAACCAATCTACGAAATCGCTGCTGCAATGCA
GGAAACAGTGGCAGAATCACAGGGTGCAGTGGGGGGCCATTTGAGGGCTTTTGGATGGACCTTTTATTTCCTT
AACCAGTTACCAGCAATTATTGCTGACAATTTGGGTAGAAGCCTTGAACGAGCACTTGCCCCACTCGGTGTCCG
CGAATGGAATGACGTTTTTTGGGTGGCCCATCCTGGTAACTGGGCAATTATTGATGCTATCGAAGCAAAGTTG
CAATTAAGTCCCGATAAATTGAGTACCGCAAGACATGTTTTCACTGAATACGGTAACATGCAGAGTGCAACCG
TTTACTTTGTAATGGATGAATTACGAAAAAGATCTGCCGTGGAGGGTAGATCAACAACTGGAGATGGTCTGCA
ATGGGGTGTTCTGTTGGGGTTTGGCCCAGGATTGTCAATTGAAACCGTGGTTCTAAGGTCCATGCCCTTGTAA 
 
Diketide-CoA synthase (DCS) (1170 bp; GC%: 47.7) 
ATGGAAGCTAACGGTTATAGAATCACTCACTCTGCCGATGGTCCAGCTACGATTTTAGCTATCGGCACTGCTAA
CCCTACTAATGTTGTTGATCAAAATGCTTATCCAGATTTCTATTTTAGAGTCACCAATTCAGAATACTTACAGGA
GTTAAAGGCTAAGTTTAGAAGAATCTGTGAGAAGGCCGCCATAAGAAAGCGGCATTTGTACTTGACCGAGGA
AATTCTTAGAGAAAATCCAAGTTTGCTGGCTCCAATGGCGCCCAGCTTCGATGCAAGACAAGCAATTGTGGTG
GAAGCGGTCCCCAAACTCGCTAAGGAAGCTGCCGAGAAGGCCATTAAGGAGTGGGGTAGACCTAAAAGCGA
CATCACGCATCTCGTTTTCTGCTCGGCATCTGGTATCGATATGCCAGGTTCCGATCTGCAGTTATTAAAATTGTT
GGGTCTTCCACCATCAGTCAATCGTGTCATGTTATATAACGTTGGTTGTCACGCTGGTGGTACAGCCTTGAGGG
TTGCCAAAGATTTGGCGGAAAATAATAGAGGCGCCCGTGTTCTGGCAGTTTGTAGCGAAGTTACTGTCCTTAG
TTATAGAGGTCCACACCCAGCACACATAGAATCACTTTTCGTCCAAGCCCTTTTCGGAGATGGAGCTGCCGCCT
TGGTCGTCGGCTCCGACCCCGTAGACGGAGTAGAAAGACCCATATTTGAAATCGCTTCCGCTTCACAAGTCAT
GTTACCCGAATCTGCTGAAGCCGTAGGAGGGCACTTGAGGGAAATTGGCTTGACCTTCCATTTAAAATCTCAG
TTACCATCCATTATTGCGTCCAATATCGAACAATCCTTGACTACAGCCTGCTCCCCATTGGGGCTGTCAGATTGG
AATCAATTGTTCTGGGCCGTGCACCCTGGAGGCAGGGCCATACTTGATCAAGTGGAAGCAAGATTGGGCCTTG
AAAAAGATCGTCTTGCCGCGACACGGCACGTACTGTCAGAATACGGTAACATGCAATCAGCCACAGTGTTGTT
CATTTTGGATGAAATGAGAAACAGGAGTGCCGCTGAGGGACACGCGACTACCGGCGAGGGATTGGATTGGG
GAGTGCTGTTGGGTTTTGGGCCAGGTTTGAGTATAGAAACTGTAGTCTTACATTCATGCAGGCTTAATTGA 
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Annex D – The fdc1 gene 
 
The sequence of the fdc1 gene is present in this annex. The sequences used in CRISPR-Cas9 
technology are highlighted: The red sequence indicates the 8 bp deletion. The red and 
underlined sequence indicates the PAM site. Green: Guide sequence Blue: 50 bp upstream 
homology (the first 17 bp of the guide sequence are also included) Yellow: 50 bp downstream 
homology. The underlined sequences indicate the FDC primers.  
 
Ferulic acid decarboxylase (FDC1) (Saccharomyces cerevisiae, 1512 bp, GC%: 40.3)   
ATGAGGAAGCTAAATCCAGCTTTAGAATTTAGAGACTTTATCCAGGTCTTAAAAGATGAAGATGACTTAATCG
AAATTACCGAAGAGATTGATCCAAATCTCGAAGTAGGTGCAATTATGAGGAAGGCCTATGAATCCCACTTACC
AGCCCCGTTATTTAAAAATCTCAAAGGTGCTTCGAAGGATCTTTTCAGCATTTTAGGTTGCCCAGCCGGTTTGA
GAAGTAAGGAGAAAGGAGATCATGGTAGAATTGCCCATCATCTGGGGCTCGACCCAAAAACAACTATCAAGG
AAATCATAGATTATTTGCTGGAGTGTAAGGAGAAGGAACCTCTCCCCCCAATCACTGTTCCTGTGTCATCTGCA
CCTTGTAAAACACATATACTTTCTGAAGAAAAAATACATCTACAAAGCCTGCCAACACCATATCTACATGTTTCA
GACGGTGGCAAGTACTTACAAACGTACGGAATGTGGATTCTTCAAACTCCAGATAAAAAATGGACTAATTGGT
CAATTGCTAGAGGTATGGTTGTAGATGACAAGCATATCACTGGTCTGGTAATTAAACCACAACATATTAGACA
AATTGCTGACTCTTGGGCAGCAATTGGAAAAGCAAATGAAATTCCTTTCGCGTTATGTTTTGGCGTTCCCCCAG
CAGCTATTTTAGTTAGTTCCATGCCAATTCCTGAAGGTGTTTCTGAATCGGATTATGTTGGCGCAATCTTGGGT
GAGTCGGTTCCAGTAGTAAAATGTGAGACCAACGATTTAATGGTTCCTGCAACGAGTGAGATGGTATTTGAGG
GTACTTTGTCCTTAACAGATACACATCTGGAAGGCCCATTTGGTGAGATGCATGGATATGTTTTCAAAAGCCAA
GGTCATCCTTGTCCATTGTACACTGTCAAGGCTATGAGTTACAGAGACAATGCTATTCTACCTGTTTCGAACCCC
GGTCTTTGTACGGATGAGACACATACCTTGATTGGTTCACTAGTGGCTACTGAGGCCAAGGAGCTGGCTATTG
AATCTGGCTTGCCAATTCTGGATGCCTTTATGCCTTATGAGGCTCAGGCTCTTTGGCTTATCTTAAAGGTGGATT
TGAAAGGGCTGCAAGCATTGAAGACAACGCCTGAAGAATTTTGTAAGAAGGTAGGTGATATTTACTTTAGGAC
AAAAGTTGGTTTTATAGTCCATGAAATAATTTTGGTGGCAGATGATATCGACATATTTAACTTCAAAGAAGTCA
TCTGGGCCTACGTTACAAGACATACACCTGTTGCAGATCAGATGGCTTTTGATGATGTCACTTCTTTTCCTTTGG
CTCCCTTTGTTTCGCAGTCATCCAGAAGTAAGACTATGAAAGGTGGAAAGTGCGTTACTAATTGCATATTTAGA
CAGCAATATGAGCGCAGTTTTGACTACATAACTTGTAATTTTGAAAAGGGATATCCAAAAGGATTAGTTGACA
AAGTAAATGAAAATTGGAAAAGGTACGGATATAAATAA 
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Annex E – PCR conditions 
 
Information relative to the PCR conditions used to PCR-amplify the genes used in this study as 
well as the conditions used for colony PCR.  
 
Table E16: Colony PCR conditions used to confirm the insertion of the genes in the plasmid.  The polymerase used was 
KAPA Taq DNA polymerase. 
Cycling step  pSP-
GM1_At4CL 
pSP-
GM1_Le4CL 
pSP-
GM1_At4CL_CUS 
pSP-
GM1_Le4CL_CUS 
Initial denaturation  95 oC, 10 min 
Denaturation  
30x 
95 oC, 30 s 
Annealing  
44 oC, 30 s 44 oC, 30 s 49 oC, 30 s 49 oC, 30 s 
Extension  72 oC, 2 min 25 
s 
72 oC, 2 min 
38 s 
72 oC, 2 min 12 s 72 oC, 2 min 12 s 
Final extension  72 oC, 5 min 
 
Table E17: Colony PCR conditions used to confirm the insertion of the genetic parts in the plasmid. The polymerase used 
was KAPA Taq DNA polymerase. 
  
 
 
 
 
 
 
Cycling step  pSP-
GM1_DCS 
pSP-
GM1_DCS_At4CL 
pSP-
GM1_DCS_At4CL_TD
H3 
pSP-
GM1_DCS_At4CL_CUR
S 
Initial denaturation  95 oC, 10 min 
Denaturation  
30x 
95 oC, 30 s 
Annealing  
44 oC, 30 s 49 oC, 30 s 44 oC, 30 s 45 oC, 30 s 
Extension  
72 oC, 2 
min 
72 oC, 2 min 13 s 72 oC, 1 min 32 s 72 oC, 2 min 
Final extension  
72 oC, 5 min 
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Table E18: Colony PCR conditions used to confirm the insertion of gblock in (KAPA Taq DNA polymerase) and the colony 
PCR conditions performed in S. cerevisiae (Phusion High-Fidelity DNA polymerase) to confirm knockout.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cycling step pCRCT_gblock fdc1 gene 
Initial denaturation  
95 oC, 10 min 95 oC, 10 min 
Denaturation  
30x 
95 oC, 30 s 95 oC, 10 s 
Annealing  
47 oC, 30 s 56.3 oC, 10 s 
Extension  
72 oC, 2 min 72 oC, 51 s 
Final extension  
72 oC, 5 min 72 oC, 10 min 
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Annex F – Calibration curves  
 
 
Figure F3: Dry weight calibration curve. The equation OD600nm = 0.8116(Dry weight) + 0.0354 was obtained with a Pearson 
Coefficient of Determination (R2) > 0.99.  
 
 
Figure F4: Ferulic acid calibration curve obtained by HPLC. The equation Area= 8E+06[Ferulic acid] -147814 was obtained with 
a Pearson Coefficient of Determination (R2) > 0.99.  
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Figure F5: 2-Methoxy-4-vinylphenol calibration curve obtained by HPLC. The equation Area= 247067[2-Methoxy-
4vinylphenol] -207.83 was obtained with a Pearson Coefficient of Determination (R2) > 0.99. 
 
 
 
 
Figure F6: Curcumin calibration curve obtained by HPLC. The equation Area= 24697[Curcumin] -25033 was obtained with a 
Pearson Coefficient of Determination (R2) > 0.99. 
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